Adeno-associated virus vector delivery of muscle-specific microdystrophins for the treatment of muscular dystrophy

Abstract

To provide gene therapy vectors, such as adeno-associated virus (AAV) vectors, expressing a miniaturized human micro-dystrophin gene, and a method of using these vectors to express micro-dystrophin in skeletal muscles including diaphragm and cardiac muscle and to protect muscle fibers from injury, increase muscle strength and reduce and / or prevent fibrosis in subjects suffering from muscular dystrophy.SOLUTION: The present invention relates to gene therapy vectors, e.g. AAV, expressing the micro-dystrophin gene to skeletal muscles including diaphragm and cardiac muscle to protect muscle fibers from injury, increase muscle strength and reduce and / or prevent fibrosis.SELECTED DRAWING: None

Description

[Technical Field]

[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 686,668 filed on 18 June 2018, U.S. Provisional Patent Application No. 62 / 740,402 filed on 2 October 2018, U.S. Provisional Patent Application No. 62 / 752,841 filed on 30 October 2018, U.S. Provisional Patent Application No. 62 / 823,649 filed on 25 March 2019, and U.S. Provisional Patent Application No. 62 / 860,220 filed on 11 June 2018, each of which is incorporated herein by reference in whole.

[0002] Reference to electronically submitted materials This application includes, as a separate part of the present disclosure, a sequence listing in computer-readable form, which is incorporated in its entirety by reference and identified as follows: filename: 53169_Seqlisting.txt; size: 60,056 bytes; date created: June 17, 2019.

[0003] The present invention provides gene therapy vectors, such as adeno-associated virus (AAV) vectors, that express a miniaturized human microdystrophin gene, and methods for using these vectors in subjects suffering from muscular dystrophy to express microdystrophin in skeletal muscle, including the diaphragm and cardiac muscle, to protect muscle fibers from damage, increase muscle strength, and reduce and / or prevent fibrosis. [Background technology]

[0004] The importance of muscle mass and strength is evident for daily activities such as spontaneous movement and breathing, as well as for bodily metabolism. A lack of muscle function leads to muscular dystrophy (MD), characterized by muscle weakness and atrophy, which severely impacts quality of life. The most well-characterized forms of MD result from mutations in genes encoding members of the dystrophin-binding protein complex (DAPC). These MDs result from membrane fragility associated with the loss of anchoring of the muscle sheath and cytoskeleton by DAPC. Duchenne muscular dystrophy (DMD) is one of the most serious muscle diseases, affecting one in 5,000 newborn boys.

[0005] DMD is caused by mutations in the DMD gene, resulting in a reduction in mRNA and the absence of dystrophin, a 427kD sarcoplasmic protein associated with the dystrophin-related protein complex (DAPC) (Hoffman et al., Cell 51(6):919~28, 1987). DAPC is composed of multiple proteins in the muscle sarcoplasmic sheath that form structural bonds between the extracellular matrix (ECM) and the cytoskeleton via dystrophin, an actin-binding protein, and α-dystroglycan, a laminin-binding protein. These structural bonds stabilize the muscle cell membrane during contraction and protect it from contraction-induced damage. Dystrophin loss leads to membrane fragility, resulting in sarcoplasmic sheath tears and calcium influx, which triggers calcium-activated protease and segmental fibrous necrosis (Straub et al., Curr Opin. Neurol., 10(2):168~75, 1997). This uncontrolled cycle of muscle degeneration and regeneration eventually depletes the muscle stem cell population (Sacco et al., Cell, 2010, 143(7): pp. 1059-71; Wallace et al., Annu Rev Physiol, 2009, 71: pp. 37-57), leading to progressive muscle weakness, fasciitis, and fibrous scarring.

[0006] Without membrane stabilization by dystrophin or microdystrophin, DMD reveals an uncontrolled cycle of tissue damage and repair, ultimately replacing lost muscle fibers with fibrous scar tissue through the proliferation of connective tissue. Fibrosis is characterized by excessive deposition of ECM matrix proteins, including collagen and elastin. ECM proteins are primarily produced from cytokines such as TGFβ, released by activated fibroblasts in response to stress and inflammation. While the main pathological features of DMD are muscle fiber degeneration and necrosis, fibrosis as a pathological consequence has equivalent consequences. The overproduction of fibrous tissue limits muscle regeneration in DMD patients and contributes to progressive muscle weakness. In one study, the presence of fibrosis in early DMD muscle biopsies was highly correlated with poor motor prognosis at 10-year follow-up (Desguerre et al., J Neuropathol Exp Neurol, 2009, 68(7):p.762~7). These results point to fibrosis as a major cause of muscle dysfunction in DMD and emphasize the need for early intervention before fibrosis becomes apparent. In patients suffering from DMD, there is a need for treatment that increases muscle strength and protects against muscle damage. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] Hoffman et al., Cell 51(6):919–28, 1987 [Non-Patent Document 2] Straub et al., Curr Opin. Neurol., 10(2):168-75, 1997. [Non-Patent Document 3] Sacco et al., Cell, 2010, 143(7):p.1059~71 [Non-Patent Document 4] Wallace et al., Annu Rev Physiol, 2009, 71:p.37~57 [Non-Patent Document 5] Desguerre et al., J Neuropathol Exp Neurol, 2009, 68(7):p.762~7 [Overview of the Initiative] [Means for solving the problem]

[0008] The present invention relates to a gene therapy vector, e.g., AAV, that expresses the microdystrophin gene in skeletal muscle, including fascia and cardiac muscle, for the purpose of protecting muscle fibers from damage, increasing muscle strength, reducing fibrosis, and / or preventing it.

[0009] This invention provides therapies and approaches to increase muscle strength and / or muscle mass using a gene therapy vector for delivering microdystrophin to combat the gene deficiencies observed in DMD. Example 2 describes a systemic gene delivery clinical trial for Duchenne muscular dystrophy, in which subjects were administered 2 × 10¹⁴ vg / kg AAVrh74.MHCK7.microdystrophin. The clinical trial described in Example 3 provides a novel central clinical protocol, including a randomized, double-blind, placebo-controlled design. At the start of the study, subjects were randomized to 2 × 10¹⁴ 14 vg / kg AAVrh74.MHCK7. Either microdystrophin or lactated Ringer's solution is administered.

[0010] The present invention provides nucleic acid molecules comprising the nucleotide sequence of SEQ ID NO: 3, 8, or 9. The present invention also provides rAAVs comprising the nucleic acid sequence of SEQ ID NO: 9 or nucleotides 1-4977 of SEQ ID NO: 8 or nucleotides 55-5021 of SEQ ID NO: 3, and rAAV particles comprising the nucleic acid sequence of SEQ ID NO: 9 or nucleotides 1-4977 of SEQ ID NO: 8 or nucleotides 55-5021 of SEQ ID NO: 3.

[0011] Another aspect of the present invention provides a composition comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 3, 8 or 9, an rAAV comprising the nucleic acid sequence of SEQ ID NO: 9 or nucleotides 1 to 4977 of SEQ ID NO: 8 or nucleotides 55 to 5021 of SEQ ID NO: 3, and an rAAV particle comprising the nucleic acid sequence of SEQ ID NO: 9 or nucleotides 1 to 4977 of SEQ ID NO: 8 or nucleotides 55 to 5021 of SEQ ID NO: 3. Any of the methods disclosed herein may be implemented using these compositions.

[0012] The present invention provides a method for treating muscular dystrophy in a human subject in need thereof, comprising the step of administering recombinant adeno-associated virus (rAAV) rAAV.MHCK7.microdystrophin, wherein the rAAV is administered at a dose of about 5.0×10 12 vg / kg to about 1.0×10 15 vg / kg by the systemic administration route. The muscular dystrophy may be Duchenne muscular dystrophy or Becker muscular dystrophy.

[0013] For example, the dose of rAAV administered is about 5.0×10 12 vg / kg to about 1.0×10 14 vg / kg, or about 5.0×10 12 vg / kg to 1.0×10 14 vg / kg, or about 5.0×10 12 vg / kg to about 2.0×10 14 vg / kg, or about 5.0×10 12 vg / kg to about 1.0×10 14 vg / kg, or about 5.0×10 12 vg / kg to about 5.0×10 13 vg / kg, or about 5.0×10 12 vg / kg to about 2.0×10 13 vg / kg, or about 5.0×10 12 vg / kg to about 1.0×10 13 vg / kg, or 1.0×10 14 vg / kg to about 1.0×10 15 vg / kg, or 1.0×10 13vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg~1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 13 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 6.0×10 14 vg / kg, or 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 15 vg / kg, or 5.0 × 10 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg~1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 6.0×10 14 vg / kg, or 5.0 × 10 13 vg / kg ~ approx. 1.0×10 15 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 6.0×10 14 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 5.0×1014 vg / kg, or 1.0×10 14 vg / kg to approximately 4.0×10 14 vg / kg, or 1.0×10 14 vg / kg to approximately 1.0×10 15 vg / kg, or 1.0×10 14 vg / kg to approximately 3.0×10 14 vg / kg, or approximately 1.0×10 14 vg / kg to approximately 2.5×10 14 vg / kg, or 1.0×10 14 vg / kg to approximately 2.0×10 14 vg / kg, or approximately 1.25×10 14 vg / kg to approximately 3.75×10 14 vg / kg, or approximately 1.25×10 14 vg / kg to 6.0×10 14 or approximately 1.25×10 14 vg / kg to 5.0×10 14 or approximately 1.25×10 14 vg / kg to 4.0×10 14 or approximately 1.25×10 14 vg / kg to 1.0×10 15 or approximately 1.25×10 14 vg / kg to approximately 3.5×10 14 vg / kg, or approximately 1.25×10 14 vg / kg to approximately 3.0×10 14 vg / kg, or approximately 1.25×10 14 vg / kg to approximately 2.75×10 14 vg / kg, or approximately 1.25×10 14 vg / kg to approximately 2.5×10 14 vg / kg, or approximately 1.25×10 14 vg / kg to approximately 2.0×10 14 vg / kg, or 1.25×10 14 vg / kg to approximately 3.75×10 14 vg / kg, or approximately 1.25×10 14 vg / kg to approximately 3.5×10 14 vg / kg, or 1.5×10 14 vg / kg to approximately 1.0×10 15vg / kg, or about 1.5×10 14 vg / kg to 6.0×10 14 or about 1.5×10 14 vg / kg to 5.0×10 14 or about 1.5×10 14 vg / kg to 4.0×10 14 or about 1.5×10 14 vg / kg to about 3.75×10 14 vg / kg, or about 1.5×10 14 vg to about 3.5×10 14 vg / kg, or about 1.5×10 14 vg / kg to about 3.25×10 14 vg / kg, or about 1.5×10 14 vg / kg to about 3.0×10 14 vg / kg, or about 1.5×10 14 vg / kg to about 2.75×10 14 vg / kg, or about 1.5×10 14 vg / kg to about 2.5×10 14 vg / kg, or about 1.5×10 14 vg / kg to about 2.0×10 14 vg / kg, or 1.75×10 14 )]]vg / kg to about 1.0×10 15 vg / kg, or about 1.75×10 14 vg / kg to 6.0×10 14 or about 1.75×10 14 vg / kg to 5.0×10 14 or about 1.75×10 14 vg / kg to 4.0×10 14 or about 1.75×10 14 vg / kg to about 3.75×10 14 vg / kg, or about 1.75×10 14 vg / kg to about 3.5×10 14 vg / kg, or about 1.75×10 14 vg / kg to about 3.25×10 14 vg / kg, or about 1.75×10 14 vg / kg to about 3.0×10 14 vg / kg, or about 1.75×10 14vg / kg ~ approx. 2.75×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.25×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg~1.0×10 15 , or approximately 2.0 × 10 14 vg / kg~6.0×10 14 , or approximately 2.0 × 10 14 vg / kg~5.0×10 14 , or approximately 2.0 × 10 14 vg / kg ~ approx. 4.0×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.25×10 14 It is vg / kg.

[0014] In one embodiment, the method of the present invention involves systemic administration of rAAV, the systemic administration route being an intravenous route, and the dose of rAAV administered is approximately 2.0 × 10⁻⁶. 14 The value is vg / kg. In another embodiment, the method of the present invention comprises systemic administration of rAAV, the systemic administration route being intravenous, and the dose of rAAV administered is 5.0 × 10⁻⁶. 12 vg / kg, or approximately 6.0 × 10⁻⁶ 12 vg / kg, or approximately 7.0 × 10⁻⁶ 12 vg / kg, or approximately 8.0 × 10⁻⁶ 12 vg / kg, or approximately 9.0 × 10⁻⁶ 12 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg, or approximately 1.25 × 10⁻⁶ 13 vg / kg, or approximately 1.5 × 10⁻⁶ 13vg / kg, or approximately 1.75 × 10⁻⁶ 13 vg / kg, or approximately 2.25 × 10⁻⁶ 13 vg / kg, or approximately 2.5 × 10⁻⁶ 13 vg / kg, or approximately 2.75 × 10⁻⁶ 13 vg / kg, or approximately 3.0 × 10⁻⁶ 13 vg / kg, or approximately 3.25 × 10⁻⁶ 13 vg / kg, or approximately 3.5 × 10⁻⁶ 13 vg / kg, or approximately 3.75 × 10⁻⁶ 13 vg / kg, or approximately 4.0 × 10⁻⁶ 13 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg, or approximately 6.0 × 10⁻⁶ 13 vg / kg, or approximately 7.0 × 10⁻⁶ 13 vg / kg, or approximately 8.0 × 10⁻⁶ 13 vg / kg, or approximately 9.0 × 10⁻⁶ 13 vg / kg, or approximately 1.0 × 10⁻⁶ 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg, or approximately 2.25 × 10⁻⁶ 14 vg / kg, or approximately 2.5 × 10⁻⁶ 14 vg / kg, or approximately 2.75 × 10⁻⁶ 14 vg / kg, or approximately 3.0 × 10⁻⁶ 14 vg / kg, or approximately 3.25 × 10⁻⁶ 14 vg / kg, or approximately 3.5 × 10⁻⁶ 14 vg / kg, or approximately 3.75 × 10⁻⁶ 14 vg / kg, or approximately 4.0 × 10⁻⁶ 14 vg / kg, or approximately 5.0 × 10⁻⁶ 14 vg / kg, or approximately 6.0 × 10⁻⁶ 14 vg / kg, or approximately 1 × 10⁻⁶ 15The concentration is in g / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin or AAVrh74.MCK.microdystrophin. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0015] In any of the methods of the present invention, the dose of rAAV may be administered at approximately 5 mL / kg to approximately 15 mL / kg, or approximately 8 mL / kg to approximately 12 mL / kg, or 8 mL / kg to approximately 10 mL / kg, or 5 mL / kg to approximately 10 mL / kg, or approximately 10 mL / kg to approximately 12 mL / kg, or approximately 10 mL / kg to approximately 15 mL / kg, or 10 mL / kg to approximately 20 mL / kg. In certain embodiments, the dose or rAAV is administered at approximately 10 mL / kg. In one embodiment, the rAAV is AAVrh74.MHCK7.microdystrophin or AAVrh74.MCK.microdystrophin. In one embodiment, the rAAV is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MCK.microdystrophin, nucleotides 56-4820 of SEQ ID NO: 5.

[0016] In any of the methods of the present invention, the dose of rAAV may be administered by injection, infusion, or implantation. For example, the dose of rAAV may be administered by infusion over approximately 1 hour. Furthermore, the dose of rAAV may be administered via an intravenous route through a peripheral limb vein, such as a peripheral brachial vein or peripheral lower limb vein. Alternatively, the infusion may be administered over approximately 30 minutes, or approximately 1.5 hours, or approximately 2 hours, or approximately 2.5 hours, or approximately 3 hours. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0017] The rAAV administered by any of the methods of the present invention may comprise the human microdystrophin nucleotide sequence of SEQ ID NO: 1, the MHCK7 promoter sequence of SEQ ID NO: 2, or SEQ ID NO: 7. Furthermore, the rAAV administered by any of the methods of the present invention comprises the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter sequence of SEQ ID NO: 2, or SEQ ID NO: 7. For example, the rAAV may comprise the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, the rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, the AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6.

[0018] In one embodiment, rAAV is AAVrh74.MCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0019] In any of the methods of the present invention, the rAAV administered is serotype AAVrh7.4.

[0020] In some embodiments, the method of the present invention treats Duchenne muscular dystrophy or Becker muscular dystrophy. A typical embodiment is a method for treating Duchenne muscular dystrophy or Becker muscular dystrophy in a human subject requiring it, comprising the step of administering a dose of recombinant adenovirus-associated (rAAV) rAAV.MHCK7 microdystrophin, the route of administration being intravenous infusion, and the dose of rAAV administered being approximately 2 × 10⁻¹⁶ over approximately 1 hour. 14The rAAV vector is expressed in vg / kg and contains the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0021] In one embodiment, the present invention provides an rAAV comprising a muscle-specific regulatory element nucleotide sequence and a nucleotide sequence encoding a microdystrophin protein. For example, the nucleotide sequence encodes a functional microdystrophin protein, and the nucleotide has sequence identity with respect to SEQ ID NO: 1, for example, at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94%, and even more typically at least 95%, 96%, 97%, 98%, 99%, or 100%, and the protein retains microdystrophin activity. The microdystrophin protein provides stability to the muscle membrane during muscle contraction, and for example, microdystrophin functions as a shock absorber during muscle contraction. In one embodiment, the rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0022] The present invention also provides an rAAV comprising a nucleotide sequence which hybridizes to the nucleic acid sequence of SEQ ID NO: 1 or its complementary sequence under stringent conditions, and which encodes a functional microdystrophin protein.

[0023] In one embodiment, rAAV is a non-repeating AAVrh74.MHCK7.microdystrophin with nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. This vector genome contains the minimum elements necessary for gene expression, including AAV2 inverted terminal repeats (ITRs), microdystrophin, SV40 introns (SD / SA), and synthetic polyadenylation (Poly A) signals, all under the control of the MHCK7 promoter / enhancer. A schematic diagram of the vector genome and expression cassette is shown in Figure 1. Using the AAVrh74 serotype, efficient gene transfer in skeletal and cardiac muscle after IV administration can be achieved.

[0024] The term "stringent" refers to conditions that are generally understood as stringent in the art. Hybridization stringency is determined primarily by temperature, ionic strength, and the concentration of denaturing agents such as formamide. Examples of stringent conditions for hybridization and washing are 0.015 M sodium chloride, 0.0015 M sodium citrate (65°C to 68°C) or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide (42°C). Sambrook et al., Molecular Cloning: A Laboratory Manual, Part 2, Cold Spring Harbor Laboratory, (Cold Spring Harbor, NY, 1989). More stringent conditions (higher temperature, lower ionic strength, higher formamide, or other denaturing agents, etc.) may be used, but the rate of hybridization will be affected. In the case of hybridization of deoxyoligonucleotides, additional typical stringent hybridization conditions include washing in 6×SSC, 0.05% sodium pyrophosphate, at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos).

[0025] Other agents may be included in the hybridization and washing buffers to reduce nonspecific and / or background hybridization. Examples include 0.1% bovine serum albumin, 0.1% polyvinylpyrrolidone, 0.1% sodium pyrophosphate, 0.1% sodium dodecyl sulfate, NaDodSO4(SDS), Ficol, Denhart's solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, but other suitable agents may also be used. The concentrations and types of these additives can be changed without substantially affecting the stringency of the hybridization conditions. Hybridization experiments are typically performed at pH 6.8–7.4, but under typical ionic strength conditions, the rate of hybridization is largely independent of pH. Anderson et al., Nucleic Acid Hybridization: A Practical Approach, Chapter 4, IRL Press Limited (Oxford, England). Hybridization conditions can be adjusted by those skilled in the art to modulate these variables and allow DNAs of different sequence relevances to form hybrids.

[0026] The term "muscle-specific regulatory element" refers to a nucleotide sequence that regulates the expression of a coding sequence that is specific to expression in muscle tissue. These regulatory elements include enhancers and promoters. The present invention provides a construct comprising a muscle-specific regulatory element MCKH7 promoter, an MCK promoter, and an MCK enhancer.

[0027] The term "operably bound" refers to a regulatory element nucleotide sequence, such as a promoter nucleotide sequence, being positioned to confer expression of that nucleotide sequence by the regulatory element.

[0028] In one embodiment, the present invention provides rAAV, in which the muscle-specific regulatory element is a human skeletal actin gene element, a cardiac actin gene element, a muscle cell-specific enhancer-binding factor (MEF), muscle creatine kinase (MCK), cleaved MCK (tMCK), myosin heavy chain (MHC), hybrid α-myosin heavy chain enhancer / MCK enhancer-promoter (MHCK7), C5-12, a mouse creatine kinase enhancer element, a skeletal fast-twitch muscle troponin c gene element, a slow-twitch muscle cardiac troponin c gene element, a slow-twitch muscle troponin i gene element, a hypoxia-inducible nuclear factor, a steroid-inducible element, or a glucocorticoid-response element (GRE).

[0029] For example, the muscle-specific regulatory element is the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or the muscle-specific regulatory element is the MCK nucleotide sequence of SEQ ID NO: 4. Furthermore, in any of the rAAV vectors of the present invention, the muscle-specific regulatory element nucleotide sequence, for example, the MHCK7 or MCK nucleotide sequence, is operably bound to a nucleotide sequence encoding a microdystrophin protein. For example, the MHCK7 promoter nucleotide sequence (SEQ ID NO: 2 or SEQ ID NO: 7) is operably bound to a human microdystrophin coding sequence (SEQ ID NO: 1) described in the construct provided in Figure 1 or Figure 2 (SEQ ID NO: 3) or Figure 13 (SEQ ID NO: 9). For example, the MCK promoter (SEQ ID NO: 4) is operably bound to a human microdystrophin coding sequence (SEQ ID NO: 1) described in the construct provided in Figure 5 or Figure 6 (SEQ ID NO: 5). In another embodiment, the present invention provides an rAAV vector comprising the nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 2, or SEQ ID NO: 1 and SEQ ID NO: 7. The present invention also provides an rAAV vector comprising the nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO: 4.

[0030] In further embodiments, the present invention provides an rAAV construct contained in a plasmid comprising the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 8. For example, the AAVrh74.MHCK7.microdystrophin vector comprises the nucleotide sequence within the ITR range of SEQ ID NO: 3, as shown in Figure 2. The rAAV vector comprises the 5' ITR, the MHCK7 promoter, the chimeric intron sequence, the coding sequence of the human microdystrophin gene, poly(A), and the 3' ITR. In one embodiment, the vector comprises nucleotides 55-5021 of SEQ ID NO: 3. The plasmid described in SEQ ID NO: 3 further comprises a pGEX plasmid backbone having ampicillin resistance and a pBR322 origin of replication.

[0031] In another embodiment, the present invention provides an rAAV comprising the nucleotide sequence of SEQ ID NO: 9. For example, the AAVrh74.MHCK7.microdystrophin vector comprises the nucleotide sequence of SEQ ID NO: 9 and is shown in Figure 13. The rAAV vector construct comprises the MHCK7 promoter, a chimeric intron sequence, the coding sequence of the human microdystrophin gene, and poly(A). In one embodiment, the rAAV vector construct further comprises ITR5' for the promoter and ITR3' for poly(A). In one embodiment, the rAAV is AAVrh74.

[0032] In another embodiment, the AAVrh74.MHCK7.microdystrophin vector contains a nucleotide sequence within the ITR range of SEQ ID NO: 8, as shown in Figure 15. The rAAV vector contains a 5'ITR, an MHCK7 promoter, a chimeric intron sequence, the coding sequence of the human microdystrophin gene, poly(A), and a 3'ITR. In one embodiment, the vector contains nucleotides 1-4977 of SEQ ID NO: 9. The plasmid described in SEQ ID NO: 3 further comprises a pGEX plasmid backbone with kanamycin resistance and a pBR322 origin of replication.

[0033] In another embodiment, the present invention provides a plasmid comprising the AAVrh74.MHCK7.microdystrophin vector construct. In one embodiment, the plasmid comprises a 5'ITR, an MHCK7 promoter, a chimeric intron sequence, a coding sequence for the human microdystrophin gene, poly(A), and a 3'ITR. In one embodiment, the plasmid comprises kanamycin resistance and optionally includes a pGEX plasmid backbone having a pBR322 replication start site. In a particular embodiment, the plasmid is described in Sequence ID No. 8 and shown in Figures 14 and 15.

[0034] The present invention provides a recombinant AAV vector comprising the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7. This rAAV vector is AAV serotype AAVrh.74.

[0035] The present invention also provides an rAAV comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence within the ITR range in SEQ ID NO: 3, the nucleotide sequence within the ITR range in SEQ ID NO: 8, or the nucleotide sequence described in SEQ ID NO: 9. This rAAV vector is AAV serotype AAVrh.74.

[0036] The rAAV vector of the present invention may be any AAV serotype such as AAVrh.74, AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, or AAV13.

[0037] The present invention also provides pharmaceutical compositions (or, as may be referred to herein simply as “compositions”) comprising any of the rAAV vectors of the present invention.

[0038] In another embodiment, the present invention provides a method for producing rAAV vector particles, comprising culturing cells transfected with any of the rAAV vectors of the present invention and recovering rAAV particles from the supernatant of the transfected cells. The present invention also provides viral particles comprising any of the recombinant AAV vectors of the present invention.

[0039] In any of the methods used to treat muscular dystrophy, the level of microdystrophin gene expression in the target cells increases after administration of rAAV. Microdystrophin gene expression in cells is detected by measuring microdystrophin protein levels by Western blotting of muscle biopsies taken before and after rAAV administration. Specifically, the level of microdystrophin protein increases by at least approximately 70% to at least approximately 80%, or at least approximately 70% to at least approximately 90%, or at least approximately 80% to at least approximately 90%, after rAAV administration compared to the level of microdystrophin before rAAV administration. For example, the level of microdystrophin protein increases by at least approximately 70%, or at least approximately 71%, or at least approximately 72%, or at least approximately 73%, or at least approximately 74%, or at least approximately 75%, or at least approximately 76%, or at least approximately 77%, or at least approximately 78%, or at least approximately 79%, or at least approximately 80%, or at least approximately 81%, or at least approximately 82%, or at least approximately 83%, or at least approximately 84%, or at least approximately 85% after administration of rAAV compared to the level of microdystrophin before administration of rAAV.

[0040] Furthermore, the expression of the microdystrophin gene in cells is detected by measuring microdystrophin protein levels by immunohistochemical analysis in muscle biopsies before and after rAAV administration. Microdystrophin protein levels increase by at least approximately 70% to at least approximately 80%, or at least approximately 70% to at least approximately 90%, or at least approximately 80% to at least approximately 90%, after rAAV administration compared to the level of microdystrophin before rAAV administration. For example, the level of microdystrophin protein increases by at least approximately 70%, or at least approximately 71%, or at least approximately 72%, or at least approximately 73%, or at least approximately 74%, or at least approximately 75%, or at least approximately 76%, or at least approximately 77%, or at least approximately 78%, or at least approximately 79%, or at least approximately 80%, or at least approximately 81%, or at least approximately 82%, or at least approximately 83%, or at least approximately 84%, or at least approximately 85% after administration of rAAV compared to the level of microdystrophin before administration of rAAV.

[0041] In any of the methods used to treat muscular dystrophy, serum CK levels in subjects decrease after rAAV administration compared to serum CK levels before rAAV administration. For example, serum CK levels in subjects decrease by approximately 65% ​​to 90%, or 65% to 95%, or 75% to 90%, or 80% to 90%, or 85% to 95%, or 87% to 95%, or 87% to 90%, compared to serum CK levels before rAAV administration, by 60 days after rAAV administration. In particular, in any of the methods for treating muscular dystrophy of the present invention, the serum CK level in the subject decreases by approximately 87% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV, or in any of the methods for treating muscular dystrophy of the present invention, the serum CK level in the subject decreases by approximately 72% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV, or in any of the methods for treating muscular dystrophy of the present invention, the serum CK level in the subject decreases by approximately 73% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV, or in any of the methods for treating muscular dystrophy of the present invention, the serum CK level in the subject decreases by approximately 78% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV, or in any of the methods for treating muscular dystrophy of the present invention, the serum CK level in the subject decreases by approximately 95% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV. In any method of treating muscular dystrophy, the number of microdystrophin-positive fibers in the affected muscle tissue increases after rAAV administration compared to the number of microdystrophin-positive fibers before rAAV administration. For example, the number of microdystrophin-positive fibers can be detected by measuring microdystrophin protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after rAAV administration.

[0042] In any method of treating muscular dystrophy, rAAV administration upregulates the expression of DAPC proteins such as α-sarcoglycan or β-sarcoglycan. For example, the level of α-sarcoglycan in a subject increases after rAAV administration compared to the level of α-sarcoglycan before rAAV administration. Furthermore, the level of β-sarcoglycan in a subject increases after rAAV administration compared to the level of β-sarcoglycan before rAAV administration. The levels of α-sarcoglycan or β-sarcoglycan are detected by measuring the α-sarcoglycan or β-sarcoglycan protein levels by Western blot or immunohistochemistry in muscle biopsies before and after rAAV administration.

[0043] In any of the methods used to treat muscular dystrophy, disease progression in subjects is slowed after administration of rAAV, as measured by one of the following: the six-minute walk test, time to stand, time to climb four stairs, time to climb and descend four stairs, Northstar Walk Assessment (NSAA), 10-meter timed test, 100-meter timed test, handheld strength measurement (HHD), timed-up-and-go, and / or gross motor subtest measurement (Bayley-III) score.

[0044] For example, in either method, subjects have an improvement in at least six locations on their NSAA score at least 270 days after rAAV administration compared to their NSAA score before rAAV administration. Furthermore, in either method, subjects have an improvement of at least approximately 0.8 seconds in their time to stand at least 270 days after rAAV administration compared to their time to stand before rAAV administration. Furthermore, in either method, subjects have an improvement of at least approximately 1.2 seconds in their time to climb four steps at least 270 days after rAAV administration compared to their time to climb four steps before rAAV administration. Furthermore, in either method, subjects have an improvement of at least approximately 7 seconds in their time to run 100 meters at least 270 days after rAAV administration compared to their time to run 100 meters before rAAV administration.

[0045] In another embodiment, the present invention provides a method for expressing the microdystrophin gene in patient cells, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022). For example, the expression of the microdystrophin gene in patient cells is detected by measuring the microdystrophin protein level by Western blot or immunohistochemistry in muscle biopsies before and after administration of the rAAV.MHCK7.microdystrophin construct. Furthermore, the expression of the microdystrophin gene is measured in the patient by further detecting the number of vector genomes per nucleus, where one vector genome per nucleus corresponds to approximately 50% microdystrophin expression, and more than one copy per nucleus corresponds to a microdystrophin expression level. For example, a cell may have 1.2 vector copies per nucleus, or 1.3 vector copies per nucleus, or 1.4 vector copies per nucleus, or 1.5 vector copies per nucleus, or 1.6 vector copies per nucleus, or 1.7 vector copies per nucleus, or 1.8 vector copies per nucleus, or 1.9 vector copies per nucleus.

[0046] In further embodiments, the present invention provides a method for reducing serum CK levels in a patient in need thereof, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022). For example, serum CK levels in the patient are reduced by at least about 65% to about 90%, or about 65% to about 95%, or about 75% to about 90%, or about 80% to about 90%, or about 85% to about 95%, or about 87% to about 95%, or about 87% to about 90%, compared to serum CK levels before administration of rAAV, by 60 days after administration of rAAV. In particular, in either of the methods for treating muscular dystrophy of the present invention, the serum CK level in the subjects decreases by approximately 87% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV, or by approximately 72% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV, or by approximately 73% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV, or by approximately 78% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV, or by approximately 95% by 60 days after administration of rAAV compared to the serum CK level before administration of rAAV.

[0047] The present invention also provides a method for increasing microdystrophin-positive fibers in patient muscle tissue, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022). For example, the number of microdystrophin-positive fibers is detected by measuring dystrophin protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after rAAV administration. Furthermore, microdystrophin gene expression is measured in the patient by further detecting the number of vector genomes per nucleus, where one vector genome per nucleus corresponds to approximately 50% microdystrophin expression, and more than one copy per nucleus corresponds to a microdystrophin expression level. For example, a cell may have 1.2 vector copies per nucleus, or 1.3 vector copies per nucleus, or 1.4 vector copies per nucleus, or 1.5 vector copies per nucleus, or 1.6 vector copies per nucleus, or 1.7 vector copies per nucleus, or 1.8 vector copies per nucleus, or 1.9 vector copies per nucleus.

[0048] In another embodiment, the present invention provides a method for increasing α-sarcoglycan expression in a patient in need thereof, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022). For example, α-sarcoglycan levels are detected by measuring α-sarcoglycan protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of rAAV.

[0049] Furthermore, the present invention provides a method for increasing β-sarcoglycan expression in a patient in need, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022). For example, β-sarcoglycan levels are detected by measuring β-sarcoglycan protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after rAAV administration.

[0050] The present invention also provides a method for treating a patient having Duchenne muscular dystrophy or Becker muscular dystrophy, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977, or SEQ ID NO: 6, nucleotides 55-5021, SEQ ID NO: 8, or nucleotides 56-5022, to slow the progression of the disease in the patient, as measured by any of the following: six-minute walk test, time to stand, time to climb four stairs, time to climb and descend four stairs, Northstar Walk Assessment (NSAA), 10-meter timed test, 100-meter timed test, handheld strength measurement (HHD), timed up and go, and / or gross motor subtest measurement (Bayley-III) score.

[0051] For example, in either method, subjects have an improvement in at least six locations on their NSAA score at least 270 days after rAAV administration compared to their NSAA score before rAAV administration. Furthermore, in either method, subjects have an improvement of at least approximately 0.8 seconds in their time to stand at least 270 days after rAAV administration compared to their time to stand before rAAV administration. Furthermore, in either method, subjects have an improvement of at least approximately 1.2 seconds in their time to climb four steps at least 270 days after rAAV administration compared to their time to climb four steps before rAAV administration. Furthermore, in either method, subjects have an improvement of at least approximately 7 seconds in their time to run 100 meters at least 270 days after rAAV administration compared to their time to run 100 meters before rAAV administration.

[0052] "Fibrosis" refers to the excessive or uncontrolled deposition of extracellular matrix (ECM) components and abnormal repair processes in damaged tissues, including skeletal muscle, cardiac muscle, liver, lungs, kidneys, and pancreas. The deposited ECM components include fibronectin and collagen, such as collagen 1, collagen 2, or collagen 3.

[0053] The present invention also provides a method for reducing or preventing fibrosis in a subject suffering from muscular dystrophy, comprising administering a therapeutically effective amount of an rAAV containing the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or an rAAV vector containing the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, the rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, the AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 3. In another embodiment, the AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9. In another embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 1-4977 of SEQ ID NO: 8 or nucleotides 56-5066 of SEQ ID NO: 6. In a further embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0054] In another embodiment, the present invention also provides a method for preventing fibrosis in a subject in need thereof, comprising administering a therapeutically effective amount of an rAAV vector comprising the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or the AAV74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022). For example, any of the rAAVs of the present invention can be administered to a subject suffering from muscular dystrophy to prevent fibrosis, for example, by administering the rAAV of the present invention expressing the human microdystrophin protein before it is observed in the subject. Furthermore, the rAAV of the present invention expressing the human microdystrophin gene can be administered to subjects at risk of developing fibrosis, such as those suffering from or diagnosed with muscular dystrophy, e.g., DMD. The rAAV of the present invention can be administered to subjects suffering from muscular dystrophy in order to prevent new fibrosis in these subjects.

[0055] The present invention considers administering rAAV before fibrosis is observed in a subject. Furthermore, rAAV can be administered to subjects at risk of developing fibrosis, such as those with or diagnosed with muscular dystrophy, e.g., DMD. rAAV can also be administered to subjects with muscular dystrophy who have already developed fibrosis, in order to prevent new fibrosis in these subjects.

[0056] The present invention also provides a method for increasing muscle strength and / or muscle mass in a subject suffering from muscular dystrophy, comprising administering a therapeutically effective amount of rAAV containing the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022).

[0057] The present invention considers administering an rAAV vector to subjects diagnosed with DMD before fibrosis is observed, or before muscle strength or muscle mass is reduced.

[0058] The present invention also considers administering rAAV containing the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022) to subjects suffering from muscular dystrophy who have already developed fibrosis, in order to prevent new fibrosis in these subjects or to reduce fibrosis in these subjects. The present invention also provides for administering an rAAV vector containing the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022) to subjects suffering from muscular dystrophy who have already experienced reduced muscle strength or muscle mass, in order to protect the muscles from further damage.

[0059] In any of the methods of the present invention, the subject may have a muscular dystrophy such as DMD or any other dystrophin-related muscular dystrophy.

[0060] In any other embodiment of the method of the present invention described herein, the serum CK level in the subject is, after administration of rAAV, compared to the serum CK level before administration of rAAV, a) At least 78% within 90, 180, or 270 days after administration; b) at least 46, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, or 85% within 270 days after administration; c) At least 72, 73, 74, or 95% within 180 days after administration; d) At least 87%, 88%, 93%, or 95% within 90 days after administration; e) At least 70% within 270 days after administration; f) 70-95% within 90, 180, or 270 days after administration; g) at least 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% within 90, 180, or 270 days after administration; and h) By 90, 180, or 270 days after administration, the decrease is at a percentage level selected from a group consisting of at least 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95%.

[0061] In another embodiment, the present invention relates to a composition for treating muscular dystrophy in a human subject requiring treatment, comprising one dose of recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin, in which case the composition is formulated for a systemic route of administration, and the dose of rAAV is approximately 1 × 10⁻⁶ 14 vg / kg ~ approx. 4×10 14 The present invention provides a composition in vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0062] For example, the composition of the present invention is approximately 5.0 × 10 12 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg~1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 5.0×10 13 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 2.0×10 13 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 1.0×10 13 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 1.0×10 15 vg / kg, or 1.0 × 10⁻⁶13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg~1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 13 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 6.0×10 14 vg / kg, or 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 15 vg / kg, or 5.0 × 10 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg~1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 6.0×10 14 vg / kg, or 5.0 × 10 13 vg / kg ~ approx. 1.0×10 15 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 6.0×10 14 vg / kg, or 1.0 × 10⁻⁶ 14vg / kg ~ approx. 5.0×10 14 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 4.0×10 14 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 1.0×10 15 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg~6.0×10 14 , or approximately 1.25 × 10 14 vg / kg~5.0×10 14 , or approximately 1.25 × 10 14 vg / kg~4.0×10 14 , or approximately 1.25 × 10 14 vg / kg~1.0×10 15 , or approximately 1.25 × 10 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 2.75×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 1.0×10 15vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg~6.0×10 14 , or approximately 1.5 × 10 14 vg / kg~5.0×10 14 , or approximately 1.5 × 10 14 vg / kg~4.0×10 14 , or approximately 1.5 × 10 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg~approx.3.5×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 3.25×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 2.75×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 1.0×10 15 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg~6.0×10 14 , or approximately 1.75 × 10 14 vg / kg~5.0×10 14 , or approximately 1.75 × 10 14 vg / kg~4.0×10 14 , or approximately 1.75 × 10 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 3.25×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14vg / kg ~ approx. 2.75×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.25×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg~1.0×10 15 , or approximately 2.0 × 10 14 vg / kg~6.0×10 14 , or approximately 2.0 × 10 14 vg / kg~5.0×10 14 , or approximately 2.0 × 10 14 vg / kg ~ approx. 4.0×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.25×10 14 The dosage of rAAV is vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0063] In one embodiment, the composition of the present invention is formulated for intravenous administration, and approximately 2.0 × 10 14The present invention comprises a dose of rAAV in vg / kg. In another embodiment, the composition of the present invention is formulated for intravenous administration and contains approximately 5.0 × 10 12 vg / kg, or approximately 6.0 × 10⁻⁶ 12 vg / kg, or approximately 7.0 × 10⁻⁶ 12 vg / kg, or approximately 8.0 × 10⁻⁶ 12 vg / kg, or approximately 9.0 × 10⁻⁶ 12 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg, or approximately 1.25 × 10⁻⁶ 13 vg / kg, or approximately 1.5 × 10⁻⁶ 13 vg / kg, or approximately 1.75 × 10⁻⁶ 13 vg / kg, or approximately 2.25 × 10⁻⁶ 13 vg / kg, or approximately 2.5 × 10⁻⁶ 13 vg / kg, or approximately 2.75 × 10⁻⁶ 13 vg / kg, or approximately 3.0 × 10⁻⁶ 13 vg / kg, or approximately 3.25 × 10⁻⁶ 13 vg / kg, or approximately 3.5 × 10⁻⁶ 13 vg / kg, or approximately 3.75 × 10⁻⁶ 13 vg / kg, or approximately 4.0 × 10⁻⁶ 13 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg, or approximately 6.0 × 10⁻⁶ 13 vg / kg, or approximately 7.0 × 10⁻⁶ 13 vg / kg, or approximately 8.0 × 10⁻⁶ 13 vg / kg, or approximately 9.0 × 10⁻⁶ 13 vg / kg, or approximately 1.0 × 10⁻⁶ 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg, or approximately 2.25 × 10⁻⁶ 14 vg / kg, or approximately 2.5 × 10⁻⁶ 14 vg / kg, or approximately 2.75 × 10⁻⁶ 14 vg / kg, or approximately 3.0 × 10⁻⁶ 14 vg / kg, or approximately 3.25 × 10⁻⁶ 14 vg / kg, or approximately 3.5 × 10⁻⁶ 14 vg / kg, or approximately 3.75 × 10⁻⁶14 vg / kg, or approximately 4.0 × 10⁻⁶ 14 vg / kg, or approximately 5.0 × 10⁻⁶ 14 vg / kg, or approximately 6.0 × 10⁻⁶ 14 vg / kg, or approximately 1 × 10⁻⁶ 15 The dosage includes rAAV. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In another embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0064] In any of the compositions of the present invention, the dose of rAAV is delivered at approximately 5 mL / kg to approximately 15 mL / kg, or approximately 8 mL / kg to approximately 12 mL / kg, or 8 mL / kg to approximately 10 mL / kg, or 5 mL / kg to approximately 10 mL / kg, or approximately 10 mL / kg to approximately 12 mL / kg, or approximately 10 mL / kg to approximately 15 mL / kg, or 10 mL / kg to approximately 20 mL / kg. In certain embodiments, the composition includes a dose of rAAV delivered at approximately 10 mL / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In another embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0065] The compositions of the present invention are formulated for administration by injection, infusion, or transplantation. For example, the compositions are formulated for administration by infusion over approximately one hour. Furthermore, the compositions of the present invention are formulated for intravenous administration through peripheral limb veins, such as peripheral brachial veins or peripheral lower limb veins. Alternatively, the infusion may be administered over approximately 30 minutes, or approximately 1.5 hours, or approximately 2 hours, or approximately 2.5 hours, or approximately 3 hours.

[0066] Any of the compositions of the present invention includes an rAAV comprising the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or an rAAV vector comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6.

[0067] In particular, the compositions of the present invention are for the treatment of Duchenne muscular dystrophy or Becker muscular dystrophy. For example, the present invention is a composition for the treatment of Duchenne muscular dystrophy or Becker muscular dystrophy in human subjects requiring it, comprising one dose of recombinant adenovirus-associated (rAAV) rAAV.MHCK7 microdystrophin, formulated for administration by intravenous infusion over approximately one hour, with a dose of rAAV administered being approximately 2 × 10⁻⁶ 14 The present invention provides a composition in vg / kg in which rAAV contains the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6.

[0068] In another embodiment, the present invention also provides a composition comprising rAAV for reducing fibrosis in subjects requiring it. Furthermore, the present invention provides a composition comprising an rAAV vector for preventing fibrosis in subjects suffering from muscular dystrophy.

[0069] The present invention also provides compositions comprising rAAV for increasing muscle strength and / or muscle mass in subjects suffering from muscular dystrophy. In further embodiments, the present invention provides compositions comprising any of the rAAVs of the present invention for the treatment of muscular dystrophy.

[0070] In any other embodiment of the composition of the present invention, after administration of the composition to a human subject in need of treatment for muscular dystrophy, the serum CK level in the subject is compared to the serum CK level before administration of the composition. a) At least 78% within 90, 180, or 270 days after administration; b) At least 46, 55, 70, or 85% within 270 days after administration; c) At least 72, 73, 74, or 95% within 180 days after administration; d) At least 87, 99, 93, or 95% within 90 days after administration; e) At least 70% within 270 days after administration; f) 70-95% within 90, 180, or 270 days after administration; g) at least 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% within 90, 180, or 270 days after administration; and h) By 90, 180, or 270 days after administration, the decrease will be at a percentage level selected from the following groups: 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95%.

[0071] In another embodiment, the present invention relates to the use of a dose of recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin for the preparation of a pharmacopoeia for the treatment of muscular dystrophy in human subjects requiring it, wherein the pharmacopoeia is formulated for a systemic route of administration, and the dose of rAAV is approximately 1 × 10⁻⁶ 14 vg / kg ~ approx. 4×10 14 The usage is provided in vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0072] For example, pharmaceuticals are approximately 5.0 x 10 12 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg~1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 5.0×10 13 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 2.0×10 13 vg / kg, or approximately 5.0 × 10⁻⁶ 12 vg / kg ~ approx. 1.0×10 13 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 1.0×10 15 vg / kg, or 1.0 × 10⁻⁶ 13vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg~1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 13 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 6.0×10 14 vg / kg, or 1.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 15 vg / kg, or 5.0 × 10 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg~1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 1.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 5.0×10 14 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg ~ approx. 6.0×10 14 vg / kg, or 5.0 × 10 13 vg / kg ~ approx. 1.0×10 15 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 6.0×10 14 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 5.0×1014 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 4.0×10 14 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 1.0×10 15 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or 1.0 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg~6.0×10 14 , or approximately 1.25 × 10 14 vg / kg~5.0×10 14 , or approximately 1.25 × 10 14 vg / kg~4.0×10 14 , or approximately 1.25 × 10 14 vg / kg~1.0×10 15 , or approximately 1.25 × 10 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 2.75×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 1.0×10 15vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg~6.0×10 14 , or approximately 1.5 × 10 14 vg / kg~5.0×10 14 , or approximately 1.5 × 10 14 vg / kg~4.0×10 14 , or approximately 1.5 × 10 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg~approx.3.5×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 3.25×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 2.75×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 1.0×10 15 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg~6.0×10 14 , or approximately 1.75 × 10 14 vg / kg~5.0×10 14 , or approximately 1.75 × 10 14 vg / kg~4.0×10 14 , or approximately 1.75 × 10 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 3.25×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 3.0×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14vg / kg ~ approx. 2.75×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.5×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.25×10 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg ~ approx. 2.0×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg~1.0×10 15 , or approximately 2.0 × 10 14 vg / kg~6.0×10 14 , or approximately 2.0 × 10 14 vg / kg~5.0×10 14 , or approximately 2.0 × 10 14 vg / kg ~ approx. 4.0×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.75×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.5×10 14 vg / kg, or approximately 2.0 × 10⁻⁶ 14 vg / kg ~ approx. 3.25×10 14 The dosage of rAAV is vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0073] In one embodiment, the pharmaceutical product of the present invention is formulated for systemic administration of a dose of rAAV, the systemic administration route being an intravenous route, and the dose of rAAV administered is approximately 2.0 × 10⁻⁶. 14 The value is vg / kg. In another embodiment, the pharmaceutical of the present invention is formulated for systemic administration of a dose of rAAV, the systemic administration route being an intravenous route, and the dose of rAAV is 5.0 × 10⁻⁶ 12 vg / kg, or approximately 6.0 × 10⁻⁶ 12 vg / kg, or approximately 7.0 × 10⁻⁶ 12 vg / kg, or approximately 8.0 × 10⁻⁶ 12 vg / kg, or approximately 9.0 × 10⁻⁶ 12 vg / kg, or approximately 1.0 × 10⁻⁶ 13 vg / kg, or approximately 1.25 × 10⁻⁶ 13 vg / kg, or approximately 1.5 × 10⁻⁶ 13 vg / kg, or approximately 1.75 × 10⁻⁶ 13 vg / kg, or approximately 2.25 × 10⁻⁶ 13 vg / kg, or approximately 2.5 × 10⁻⁶ 13 vg / kg, or approximately 2.75 × 10⁻⁶ 13 vg / kg, or approximately 3.0 × 10⁻⁶ 13 vg / kg, or approximately 3.25 × 10⁻⁶ 13 vg / kg, or approximately 3.5 × 10⁻⁶ 13 vg / kg, or approximately 3.75 × 10⁻⁶ 13 vg / kg, or approximately 4.0 × 10⁻⁶ 13 vg / kg, or approximately 5.0 × 10⁻⁶ 13 vg / kg, or approximately 6.0 × 10⁻⁶ 13 vg / kg, or approximately 7.0 × 10⁻⁶ 13 vg / kg, or approximately 8.0 × 10⁻⁶ 13 vg / kg, or approximately 9.0 × 10⁻⁶ 13 vg / kg, or approximately 1.0 × 10⁻⁶ 14 vg / kg, or approximately 1.25 × 10⁻⁶ 14 vg / kg, or approximately 1.5 × 10⁻⁶ 14 vg / kg, or approximately 1.75 × 10⁻⁶ 14 vg / kg, or approximately 2.25 × 10⁻⁶ 14 vg / kg, or approximately 2.5 × 10⁻⁶ 14 vg / kg, or approximately 2.75 × 10⁻⁶ 14vg / kg, or approximately 3.0 × 10⁻⁶ 14 vg / kg, or approximately 3.25 × 10⁻⁶ 14 vg / kg, or approximately 3.5 × 10⁻⁶ 14 vg / kg, or approximately 3.75 × 10⁻⁶ 14 vg / kg, or approximately 4.0 × 10⁻⁶ 14 vg / kg, or approximately 5.0 × 10⁻⁶ 14 vg / kg, or approximately 6.0 × 10⁻⁶ 14 vg / kg, or approximately 1 × 10⁻⁶ 15 The value is vg / kg. In one embodiment, rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, AAVrh74.MHCK7.microdystrophin is AAVrh74.MHCK7.microdystrophin of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. In one embodiment, rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, AAVrh74.MCK.microdystrophin is AAVrh74.MCK.microdystrophin of nucleotides 56-4820 of SEQ ID NO: 5.

[0074] In any use of the present invention, the medicament comprises a dose of rAAV of about 5 mL / kg to about 15 mL / kg, or about 8 mL / kg to about 12 mL / kg, or 8 mL / kg to about 10 mL / kg, or 5 mL / kg to about 10 mL / kg, or about 10 mL / kg to 12 mL / kg, or about 10 mL / kg to 15 mL / kg, or 10 mL / kg to about 20 mL / kg. In certain embodiments, the dose or rAAV is about 10 mL / kg. In one embodiment, the rAAV is AAVrh74.MHCK7.microdystrophin. In one embodiment, the AAVrh74.MHCK7.microdystrophin is the AAVrh74.MHCK7.microdystrophin of SEQ ID NO: 9, nucleotides 55 to 5021 of SEQ ID NO: 3, nucleotides 1 to 4977 of SEQ ID NO: 8, or nucleotides 56 to 5022 of SEQ ID NO: 6. In one embodiment, the rAAV is AAVrh74.MHCK.microdystrophin. In one embodiment, the AAVrh74.MCK.microdystrophin is the AAVrh74.MCK.microdystrophin of nucleotides 56 to 4820 of SEQ ID NO: 5.

[0075] In any use of the present invention, the medicament is formulated for administration by injection, infusion or transplantation. For example, the medicament is formulated for administration by infusion over about 1 hour. Further, the medicament is formulated for intravenous administration through a peripheral limb vein such as a peripheral arm vein or a peripheral leg vein. Alternatively, the infusion may be administered over about 30 minutes, or about 1.5 hours, or about 2 hours, or about 2.5 hours, or about 3 hours.

[0076] In any use of the present invention, the medicament comprises an rAAV comprising the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter sequence of SEQ ID NO: 2 or SEQ ID NO: 7, or an rAAV comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55 to 5021 of SEQ ID NO: 3, nucleotides 1 to 4977 of SEQ ID NO: 8, or nucleotides 56 to 5022 of SEQ ID NO: 6.

[0077] A particular use of the present invention is for the preparation of a medicament for the treatment of Duchenne muscular dystrophy or Becker muscular dystrophy. For example, the present invention provides the use of a dose of recombinant adeno-associated virus (rAAV) rAAV.MHCK7 microdystrophin for the preparation of a medicament for treating a Duchenne muscular dystrophy or Becker muscular dystrophy human subject who needs it, wherein the medicament is formulated for administration by intravenous infusion over about 1 hour, and the dose of rAAV administered is about 2×10 14 vg / kg, and the rAAV comprises the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55 to 5021 of SEQ ID NO: 3, nucleotides 1 to 4977 of SEQ ID NO: 8, or nucleotides 56 to 5022 of SEQ ID NO: 6.

[0078] In a further embodiment, the present invention provides the use of rAAV for the preparation of a medicament for reducing fibrosis in a subject who needs it. For example, the subject who needs it has a muscular dystrophy such as DMD or any other dystrophin-related muscular dystrophy.

[0079] In another embodiment, the present invention provides the use of rAAV for the preparation of a medicament for preventing fibrosis in a subject suffering from muscular dystrophy.

[0080] Furthermore, the present invention provides the use of rAAV for the preparation of a medicament for increasing muscle strength and / or muscle mass in a subject suffering from muscular dystrophy.

[0081] The present invention also provides the use of rAAV for the preparation of a medicament for the treatment of muscular dystrophy.

[0082] The present invention also provides the use of an rAAV vector comprising the human microdystrophin nucleotide sequence of SEQ ID NO: 1 and the MHCK7 promoter nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 7 for the preparation of a pharmaceutical for the treatment of muscular dystrophy, or an rAAV vector comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55-5021 of SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6 for the treatment of muscular dystrophy.

[0083] In any other embodiment of the use of the present invention, serum CK levels in a subject are compared to serum CK levels before administration of rAAV to the subject after administration of rAAV. a) At least 78% within 90, 180, or 270 days after administration; b) At least 46, 55, 70, or 95% within 270 days after administration; c) At least 72, 73, 74, or 95% within 180 days after administration; d) At least 87%, 88%, 93%, or 95% within 90 days after administration; e) At least 70% within 270 days after administration; f) 70-95% within 90, 180, or 270 days after administration; g) at least 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% within 90, 180, or 270 days after administration; and h) By 90, 180, or 270 days after administration, the decrease will be at a percentage level selected from the following groups: 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95%.

[0084] In either the use of a composition for treating muscular dystrophy or a pharmaceutical for treating muscular dystrophy, the level of microdystrophin gene expression in the target cells increases after administration of the composition or pharmaceutical. Microdystrophin gene expression in cells is detected by measuring microdystrophin protein levels by Western blotting of muscle biopsies taken before and after administration of the composition or pharmaceutical. In particular, the level of microdystrophin protein increases by at least about 70% to at least about 80%, or at least about 70% to at least about 90%, or at least about 80% to at least about 90%, after administration of the composition or pharmaceutical, compared to the level of microdystrophin before administration of the composition or pharmaceutical. For example, the level of microdystrophin protein increases by at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, after administration of the composition, compared to the level of microdystrophin before administration of the composition or pharmaceutical.

[0085] Furthermore, the expression of the microdystrophin gene in cells is detected by measuring microdystrophin protein levels by immunohistochemical testing in muscle biopsies before and after administration of the composition or pharmaceutical. Microdystrophin protein levels increase by at least approximately 70% to at least approximately 80%, or at least approximately 70% to at least approximately 90%, or at least approximately 80% to at least approximately 90%, after administration of rAAV compared to the level of microdystrophin before administration of the composition or pharmaceutical. For example, the level of microdystrophin protein increases by at least about 70%, or at least about 71%, or at least about 72%, or at least about 73%, or at least about 74%, or at least about 75%, or at least about 76%, or at least about 77%, or at least about 78%, or at least about 79%, or at least about 80%, or at least about 81%, or at least about 82%, or at least about 83%, or at least about 84%, or at least about 85%, after administration of the composition or drug, compared to the level of microdystrophin before administration of the composition or drug.

[0086] In any of the compositions used to treat muscular dystrophy, serum CK levels in subjects decrease after administration of rAAV compared to serum CK levels before administration of the composition or drug. For example, serum CK levels in subjects decrease by approximately 65% ​​to approximately 90%, or approximately 65% ​​to approximately 95%, or approximately 75% to approximately 90%, or approximately 80% to approximately 90%, or approximately 85% to approximately 95%, or approximately 87% to approximately 95%, or approximately 87% to approximately 90%, compared to serum CK levels before administration of the composition or drug, up to 60 days after administration of the composition or drug. In particular, with any of the compositions for treating muscular dystrophy of the present invention, the serum CK level in the subject decreases by approximately 87% by 60 days after administration of the composition or the drug compared to the serum CK level before administration of the composition or the drug, or with any use of the composition for treating muscular dystrophy of the present invention or the drug for treating muscular dystrophy of the present invention, the serum CK level in the subject decreases by approximately 72% by 60 days after administration of the composition or the drug compared to the serum CK level before administration of the composition or the drug, or with any of the compositions for treating muscular dystrophy of the present invention, the serum CK level in the subject decreases by approximately 87% by 60 days after administration of the composition or the drug compared to the serum CK level before administration of the composition or the drug. In addition to the pre-administration serum CK level, serum CK levels in the subject decrease by approximately 73% by 60 days after administration of the composition or pharmaceutical, or in either case of the use of the composition or pharmaceutical for treating muscular dystrophy of the present invention, serum CK levels in the subject decrease by approximately 78% by 60 days after administration of the composition or pharmaceutical, or in either case of the use of the composition or pharmaceutical for treating muscular dystrophy of the present invention, serum CK levels in the subject decrease by approximately 95% by 60 days after administration of the composition or pharmaceutical, compared to the pre-administration serum CK level. In either case of the use of the composition or pharmaceutical for treating muscular dystrophy, the number of microdystrophin-positive fibers in the subject's muscle tissue increases after administration of the composition or pharmaceutical compared to the number of microdystrophin-positive fibers before administration of the composition or pharmaceutical.For example, the number of microdystrophin-positive fibers can be detected by measuring microdystrophin protein levels in muscle biopsies taken before and after administration of a composition or pharmaceutical by Western blotting or immunohistochemistry.

[0087] In either the use of a composition or a pharmaceutical for the treatment of muscular dystrophy, administration of the composition or pharmaceutical upregulates the expression of DAPC proteins such as α-sarcoglycan or β-sarcoglycan. For example, the level of α-sarcoglycan in a subject increases after administration of the composition or pharmaceutical compared to the level of α-sarcoglycan before administration of the composition or pharmaceutical. Furthermore, the level of β-sarcoglycan in a subject increases after administration of the composition or pharmaceutical compared to the level of β-sarcoglycan before administration of the composition or pharmaceutical. The levels of α-sarcoglycan or β-sarcoglycan are detected by measuring the α-sarcoglycan or β-sarcoglycan protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of the composition or pharmaceutical.

[0088] In either the use of a composition for the treatment of muscular dystrophy or a medicine for the treatment of muscular dystrophy, disease progression in the subject is slowed after administration of the composition or medicine, as measured by any of the following: the six-minute walk test, time to stand, time to climb four stairs, time to climb and descend four stairs, Northstar Walk Assessment (NSAA), 10-meter timed test, 100-meter timed test, handheld strength measurement (HHD), timed-up-and-go, and / or gross motor subtest measurement (Bayley-III) score.

[0089] For example, after administration of a composition for treating muscular dystrophy or use of a medicine for treating muscular dystrophy, the subject has at least six improvements in the NSAA score at least 270 days after administration of the composition or medicine, compared to the NSAA score before administration of rAAV. Furthermore, in either method, the subject has an improvement of at least about 0.8 seconds in the time to stand up at least 270 days after administration of the composition or medicine, compared to the time to stand up before administration of the composition or medicine. Furthermore, in either method or use of the present invention, the subject has an improvement of at least about 1.2 seconds in the time to climb four steps at least 270 days after administration of the composition or medicine, compared to the time to climb four steps test before administration of the composition or medicine. Furthermore, in either method or use of the present invention, the subject has an improvement of at least about 7 seconds in the time to run 100 meters at least 270 days after administration of the composition or medicine, compared to the time to run 100 meters at least 270 days after administration of the composition or medicine.

[0090] In another embodiment, the present invention provides a composition for expressing the microdystrophin gene in patient cells, comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022). In a further embodiment, the present invention provides the use of doses of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022) for the preparation of a pharmacopoeia for expressing the microdystrophin gene in patient cells. For example, the expression of the microdystrophin gene in patient cells is detected by measuring microdystrophin protein levels by Western blot or immunohistochemistry in muscle biopsies before and after administration of the rAAV.MHCK7.microdystrophin construct. Furthermore, microdystrophin gene expression is measured in patients by further detecting the number of vector genomes per nucleus, where one vector genome per nucleus corresponds to approximately 50% microdystrophin expression, and more than one copy per nucleus corresponds to a microdystrophin expression level. For example, a cell may have 1.2 vector copies per nucleus, or 1.3 vector copies per nucleus, or 1.4 vector copies per nucleus, or 1.5 vector copies per nucleus, or 1.6 vector copies per nucleus, or 1.7 vector copies per nucleus, or 1.8 vector copies per nucleus, or 1.9 vector copies per nucleus.

[0091] In further embodiments, the present invention provides a composition for reducing serum CK levels in patients requiring it, comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022). Furthermore, the present invention provides the use of doses of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022) for the preparation of a pharmacopoeia for reducing serum CK levels in patient cells requiring it. For example, serum CK levels in patients decrease by at least approximately 65% ​​to approximately 90%, or approximately 65% ​​to approximately 95%, or approximately 75% to approximately 90%, or approximately 80% to approximately 90%, or approximately 85% to approximately 95%, or approximately 87% to approximately 95%, or approximately 87% to approximately 90%, compared to serum CK levels before administration of the composition or pharmaceutical, by 60 days after administration of the composition or pharmaceutical. In particular, serum CK levels in the subjects decrease by approximately 87% by 60 days after administration of the composition or drug compared to serum CK levels before administration of the composition or drug, or by approximately 72% by 60 days after administration of the composition or drug compared to serum CK levels before administration of the composition or drug, or by approximately 73% by 60 days after administration of the composition or drug compared to serum CK levels before administration of the composition or drug, or by approximately 78% by 60 days after administration of the composition or drug compared to serum CK levels before administration of the composition or drug, or by approximately 95% by 60 days after administration of the composition or drug compared to serum CK levels before administration of the composition or drug.

[0092] The present invention also provides a composition for increasing microdystrophin-positive fibers in patient muscle tissue, comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6. Furthermore, the present invention provides the use of doses of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9, SEQ ID NO: 3, nucleotides 1-4977 of SEQ ID NO: 8, or nucleotides 56-5022 of SEQ ID NO: 6 for the preparation of a pharmacopoeia for increasing microdystrophin-positive fibers in patient muscle tissue. For example, the number of microdystrophin-positive fibers is detected by measuring dystrophin protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of the composition or pharmacopoeia. Furthermore, microdystrophin gene expression is measured in patients by further detecting the number of vector genomes per nucleus, where one vector genome per nucleus corresponds to approximately 50% microdystrophin expression, and more than one copy per nucleus corresponds to a microdystrophin expression level. For example, a cell may have 1.2 vector copies per nucleus, or 1.3 vector copies per nucleus, or 1.4 vector copies per nucleus, or 1.5 vector copies per nucleus, or 1.6 vector copies per nucleus, or 1.7 vector copies per nucleus, or 1.8 vector copies per nucleus, or 1.9 vector copies per nucleus.

[0093] In another embodiment, the present invention provides a composition for increasing α-sarcoglycan expression in patients who require it, comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022). The present invention also provides the use of doses of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022) for the preparation of a pharmacopoeia for increasing α-sarcoglycan expression in patients who require it. For example, α-sarcoglycan levels are detected by measuring α-sarcoglycan protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of the composition or pharmacopoeia.

[0094] Furthermore, the present invention provides a composition for increasing β-sarcoglycan expression in patients who require it, comprising the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022). The present invention also provides the use of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 3 (nucleotides 55-5021), SEQ ID NO: 8 (nucleotides 1-4977), or SEQ ID NO: 6 (nucleotides 56-5022) for the preparation of a pharmacopoeia for increasing β-sarcoglycan expression in patients who require it. For example, β-sarcoglycan levels are detected by measuring β-sarcoglycan protein levels by Western blotting or immunohistochemistry in muscle biopsies before and after administration of the composition or pharmacopoeia.

[0095] The present invention also provides for the use of a dose of the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9, nucleotides 55 to 5021 of SEQ ID NO: 3, nucleotides 1 to 4977 of SEQ ID NO: 8, or nucleotides 56 to 5022 of SEQ ID NO: 6 for the preparation of a medicament for treating a patient having Duchenne muscular dystrophy or Becker muscular dystrophy such that administration of the medicament results in a progression of the disease in the patient that is slower as measured by any of the six-minute walk test, time to rise from a chair, time to climb four steps, time to climb and descend four steps, North Star Ambulatory Assessment (NSAA), 10-meter timed test, 100-meter timed test, hand-held dynamometry (HHD), timed up and go, and / or gross motor subtest measurement (Bayley-III) score.

[0096] For example, the subject has at least six improvements in the NSAA score at least 270 days after administration of the composition or medicament as compared to the NSAA score prior to administration of the composition or medicament. Further, the subject has at least about 0.8 seconds improvement in the time to rise from a chair at least 270 days after administration of the composition or medicament as compared to the time to rise from a chair prior to administration of the composition or medicament. Further, the subject has at least about 1.2 seconds improvement in the time to climb four steps test at least 270 days after administration of the composition or medicament as compared to the time to climb four steps test prior to administration of the composition or medicament. Further, the subject has at least about 7 seconds improvement in the 100-meter timed test at least 270 days after administration of the composition or medicament as compared to the 100-meter timed test prior to administration of the composition or medicament. The present invention provides, for example, the following items. (Item 1) A method for treating muscular dystrophy in a human subject who needs it, comprising the step of administering recombinant adeno-associated virus (rAAV) rAAV.MHCK7.microdystrophin, where the rAAV is administered using a systemic route of administration at about 5.0×1012 vg / kg ~ approx. 1.0×10 15 The method of administration in a given dose. (Item 2) The systemic administration route is an intravenous route, and the dose of rAAV administered is approximately 2 ×10 14 The method described in item 1, which is vg / kg. (Item 3) The method according to item 1 or 2, wherein the aforementioned dose of rAAV is administered at a concentration of approximately 10 mL / kg. (Item 4) The method according to any one of items 1 to 3, wherein the rAAV is administered by injection, infusion, or implantation. (Item 5) The method according to any one of items 1 to 4, wherein the rAAV is administered by infusion over a period of approximately one hour. (Item 6) The method according to any one of items 1 to 5, wherein the rAAV is administered via an intravenous route through a peripheral limb vein. (Item 7) The method according to any one of items 1 to 6, wherein the rAAV comprises the human microdystrophin nucleotide sequence of SEQ ID NO: 1. (Item 8) The method according to any one of items 1 to 7, wherein the rAAV comprises the MHCK7 promoter sequence of SEQ ID NO: 2 or SEQ ID NO: 7. (Item 9) The method according to any one of items 1 to 8, wherein the rAAV is of serotype AAVrh.74. (Item 10) The method according to any one of items 1 to 9, wherein the rAAV comprises the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 11) The method according to any one of items 1 to 10, wherein the muscular dystrophy is Duchenne muscular dystrophy or Becker muscular dystrophy. (Item 12) The aforementioned human subject suffers from Duchenne muscular dystrophy, and the rAAV is administered intravenously over approximately 1 hour, resulting in approximately 2 × 10⁻¹⁶ doses. 14 The method according to any one of items 1 to 11, wherein the rAAV is administered in a dose of vg / kg and comprises the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 13) The method according to any one of items 1 to 12, wherein the level of microdystrophin gene expression in the target cells increases after administration of rAAV compared to the level of microdystrophin gene expression before administration of rAAV. (Item 14) The method according to item 13, wherein the expression of the microdystrophin gene in the cells is detected by measuring the microdystrophin protein level by Western blotting in muscle biopsies taken before and after administration of rAAV. (Item 15) The method according to item 14, wherein the aforementioned level of microdystrophin protein increases by at least 72% after administration of rAAV compared to the level of microdystrophin before administration of rAAV. (Item 16) The expression of the microdystrophin gene in the aforementioned cells was found to be related to the microdystrophin protein by immunohistochemical examination of muscle biopsies before and after administration of rAAV. The method described in item 13, which is detected by measuring the quality level. (Item 17) The method according to item 16, wherein the level of microdystrophin protein increases by at least 72% after administration of rAAV compared to the level of microdystrophin before administration of rAAV. (Item 18) The method according to any one of items 1 to 12, wherein the serum CK level in the subject decreases after administration of the rAAV compared to the serum CK level before administration of the rAAV. (Item 19) The method according to item 18, wherein the serum CK level in the subject decreases by 87% by 60 days after administration of the rAAV compared to the serum CK level before administration of the rAAV. (Item 20) The method according to any one of items 1 to 12, wherein the number of microdystrophin-positive fibers in the target muscle tissue increases after administration of the rAAV compared to the number of microdystrophin-positive fibers before administration of the rAAV. (Item 21) The method according to item 20, wherein the number of microdystrophin-positive fibers is detected by measuring the microdystrophin protein level by Western blotting in muscle biopsies before and after administration of rAAV. (Item 22) The method according to item 20, wherein the number of microdystrophin-positive fibers is detected by measuring the microdystrophin protein level by immunohistochemical examination in muscle biopsies before and after administration of rAAV. (Item 23) The method according to any one of items 1 to 12, wherein the level of α-sarcoglycan in the subject increases after administration of rAAV compared to the level of α-sarcoglycan before administration of rAAV. (Item 24) The method according to item 23, wherein the aforementioned level of α-sarcoglycan is detected by measuring the α-sarcoglycan protein level by Western blotting in muscle biopsies before and after administration of rAAV. (Item 25) The method according to item 23, wherein the number of α-sarcoglycans is detected by measuring α-sarcoglycan protein levels by immunohistochemical examination in muscle biopsies before and after administration of rAAV. (Item 26) The method according to any one of items 1 to 12, wherein the level of β-sarcoglycan in the subject increases after administration of rAAV compared to the level of β-sarcoglycan before administration of rAAV. (Item 27) The method according to item 26, wherein the aforementioned level of β-sarcoglycan is detected by measuring β-sarcoglycan protein levels by Western blotting in muscle biopsies before and after administration of rAAV. (Item 28) The method according to item 26, wherein the number of β-sarcoglycans is detected by measuring the β-sarcoglycan protein level by immunohistochemical examination in muscle biopsies before and after administration of rAAV. (Item 29) The progression of the disease in the aforementioned subjects was assessed using the following tests: a six-minute walking test, time to stand up, time to climb four stairs, time to climb and descend four stairs, and the North Star Walk Assessment (N The method according to any one of items 1 to 12, which slows down after administration of rAAV as measured by any of the following: SAA, 10-meter timed test, 100-meter timed test, handheld strength measurement (HHD), timed-up-and-go, and / or gross motor subtest measurement (Bayley-III) score. (Item 30) The method according to item 25, wherein the subject has an improvement in at least six locations in the NSAA score at least 270 days after rAAV administration compared to the NSAA score before rAAV administration. (Item 31) The method according to item 25, wherein the subject has an improvement of at least 0.8 seconds in the time to stand up at least 270 days after administration of the rAAV compared to the time to stand up before administration of the rAAV. (Item 32) The method according to item 25, wherein the subject has an improvement of at least about 1.2 seconds in the time to climb four steps test at least 270 days after administration of the rAAV compared to the time to climb four steps test before administration of the rAAV. (Item 33) The method according to item 25, wherein the subject has an improvement of at least 7 seconds in the 100-meter time test at least 270 days after administration of the rAAV, compared to the 100-meter time test before administration of the rAAV. (Item 34) A method for expressing the microdystrophin gene in patient cells, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 35) The method according to item 30, wherein the expression of the microdystrophin gene in the patient cells is detected by measuring the microdystrophin protein level by Western blotting in muscle biopsies before and after administration of the rAAV.MHCK7.microdystrophin construct. (Item 36) The method according to item 30, wherein the expression of the microdystrophin gene in the patient cells is detected by measuring the microdystrophin protein level by immunohistochemical examination in muscle biopsies before and after administration of the rAAV.MHCK7.microdystrophin construct. (Item 37) The method according to item 30, which is measured in the patient by detecting more than one rAAV vector genome copy per nucleus in expression of the microdystrophin gene. (Item 38) A method for reducing serum CK levels in a patient requiring such reduction, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 39) The method according to item 34, wherein the serum CK level in the patient is reduced by at least 87% by 60 days after administration of the rAAV compared to the serum CK level before administration of the rAAV. (Item 40) A method for increasing microdystrophin-positive fibers in patient muscle tissue, A method comprising administering to a patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 41) The method according to item 36, wherein the number of microdystrophin-positive fibers is detected by measuring the dystrophin protein level by Western blotting in muscle biopsies before and after administration of rAAV. (Item 42) The method according to item 36, wherein the number of microdystrophin-positive fibers is detected by measuring the dystrophin protein level by immunohistochemical examination in muscle biopsies before and after administration of rAAV. (Item 43) The method according to item 36, wherein the number of microdystrophin-positive fibers is measured by detecting rAAV vector genome copies in which there is more than one per nucleus. (Item 44) A method for increasing the expression of α-sarcoglycans in a patient requiring such treatment, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 45) The method according to item 40, wherein the aforementioned level of α-sarcoglycan is detected by measuring the α-sarcoglycan protein level by Western blotting in muscle biopsies before and after administration of rAAV. (Item 46) The method according to item 40, wherein the number of α-sarcoglycans is detected by measuring the α-sarcoglycan protein level by immunohistochemical examination in muscle biopsies before and after administration of rAAV. (Item 47) A method for increasing the expression of β-sarcoglycans in a patient requiring such treatment, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 48) The method according to item 43, wherein the level of β-sarcoglycan is detected by measuring the level of β-sarcoglycan protein by Western blotting in muscle biopsies before and after administration of rAAV. (Item 49) The method according to item 43, wherein the number of β-sarcoglycans is detected by measuring the β-sarcoglycan protein level by immunohistochemical examination in muscle biopsies before and after administration of rAAV. (Item 50) A method for treating a patient having Duchenne muscular dystrophy or Becker muscular dystrophy, comprising administering to the patient the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of SEQ ID NO: 9 or SEQ ID NO: 3, nucleotides 55-5021, to delay the progression of the disease in the patient, as measured by any of the following: six-minute walk test, time to stand, time to climb four stairs, time to climb and descend four stairs, Northstar Walk Assessment (NSAA), 10-meter timed test, 100-meter timed test, handheld strength measurement (HHD), timed up and go, and / or gross motor subtest measurement (Bayley-III) score. (Item 51) The method according to item 46, wherein the subject has an improvement in at least six locations in the NSAA score at least 90 days after rAAV administration compared to the NSAA score before rAAV administration. (Item 52) The method according to item 46, wherein the subject has an improvement of at least 0.8 seconds in the time to stand up at least 90 days after administration of the rAAV compared to the time to stand up before administration of the rAAV. (Item 53) The method according to item 46, wherein the subject has an improvement of at least about 1.2 seconds in the time to climb four steps at least 90 days after administration of the rAAV compared to the time to climb four steps test before administration of the rAAV. (Item 54) The method according to item 46, wherein the subject has an improvement of at least 7 seconds in the 100-meter time test at least 90 days after administration of the rAAV compared to the 100-meter time test before administration of the rAAV. (Item 55) A composition for treating muscular dystrophy in human subjects requiring it, comprising recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin, formulated for a systemic route of administration, wherein the dose of rAAV is approximately 5 × 10⁻¹⁴ 12 vg / kg~approx.1.0×10 15 A composition with a concentration of vg / kg. (Item 56) The systemic administration route is an intravenous route, and the dose of rAAV is approximately 2 × 10 14 The composition described in item 51, which is vg / kg. (Item 57) The composition according to item 51 or 52, wherein the dose of rAAV is approximately 10 mL / kg. (Item 58) The composition according to any one of items 51 to 53, wherein the composition is formulated for administration by injection, infusion, or implantation. (Item 59) The composition according to any one of items 51 to 53, wherein the composition is formulated for administration by infusion over approximately one hour. (Item 60) The composition according to any one of items 51 to 53, wherein the dose of the composition is formulated for intravenous administration through a peripheral limb vein. (Item 61) The composition according to any one of items 51 to 56, wherein the rAAV comprises the human microdystrophin nucleotide sequence of SEQ ID NO: 1. (Item 62) The composition according to any one of items 51 to 57, wherein the rAAV comprises the MHCK7 promoter sequence of SEQ ID NO: 2 or SEQ ID NO: 7. (Item 63) The composition according to any one of items 51 to 58, wherein the rAAV is of serotype AAVrh.74. (Item 64) The composition according to any one of items 51 to 59, wherein the rAAV comprises the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55 to 5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 65) The composition according to any one of items 51 to 60, wherein the muscular dystrophy is Duchenne muscular dystrophy or Becker muscular dystrophy. (Item 66) A composition for treating Duchenne muscular dystrophy in human subjects requiring it, comprising recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin, Intravenous infusion delivers approximately 2 x 10 units over about 1 hour. 14 Formulated for administration at a dose of vg / kg, A composition wherein the rAAV comprises the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 67) The use of recombinant adenovirus-associated (rAAV) rAAV.MHCK7.microdystrophin for the preparation of a pharmaceutical for the treatment of muscular dystrophy in human subjects requiring it, wherein the pharmaceutical is formulated for a systemic route of administration and approximately 1 × 10⁻⁶ 14 vg / kg ~ approx. 4×10 14 Use including doses of rAAV in vg / kg. (Item 68) The aforementioned pharmaceutical product is formulated for intravenous administration, and the dose of the aforementioned rAAV is approximately 2 × 10 14 Use as described in item 55, vg / kg. (Item 69) The use described in item 63 or 64, where the aforementioned dose of rAAV is approximately 10 mL / kg. (Item 70) The use of the medicament as described in any one of items 63 to 65, wherein the medicament is formulated for administration by injection, infusion, or transplantation. (Item 71) The use described in any one of items 63 to 65, wherein the aforementioned pharmaceutical is formulated for administration by infusion over approximately one hour. (Item 72) The use of the aforementioned pharmaceutical product as described in any one of items 63 to 65, wherein the pharmaceutical product is formulated for intravenous administration through a peripheral limb vein. (Item 73) The use described in any one of items 63 to 68, wherein the rAAV comprises the human microdystrophin nucleotide sequence of SEQ ID NO: 1. (Item 74) The use described in any one of items 63 to 69, wherein the rAAV contains the MHCK7 promoter sequence of SEQ ID NO: 2 or SEQ ID NO: 7. (Item 75) The use described in any one of items 63-70, wherein the rAAV is of serotype AAVrh.74. (Item 76) The use described in any one of items 63 to 70, wherein the rAAV comprises the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 77) The use described in any one of items 63 to 71, wherein the muscular dystrophy is Duchenne muscular dystrophy or Becker muscular dystrophy. (Item 78) The use of recombinant adenovirus-associated (rAAV) rAAV.MHCK7 microdystrophin for the preparation of a pharmaceutical for the treatment of Duchenne muscular dystrophy in human subjects requiring it, wherein the pharmaceutical is administered by intravenous infusion over approximately one hour. Formulated for use, approximately 2 x 10 14Use comprising a dose of vg / kg of the rAAV, wherein the rAAV contains the AAVrh74.MHCK7.microdystrophin construct nucleotide sequence of nucleotides 55-5021 of SEQ ID NO: 9 or SEQ ID NO: 3. (Item 79) The serum CK level in the subject was, compared to the serum CK level before administration of rAAV, after administration of rAAV, a) At least 78% within 90, 180, or 270 days after the administration; b) at least 46, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, or 85% within 270 days after the administration; c) at least 72, 73, 74, or 95% within 180 days after the administration; d) at least 87, 88, 93, or 95% within 90 days after the administration; e) at least 70% within 270 days after the administration; f) 70-95% within 90, 180, or 270 days after the administration; g) at least 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% within 90, 180, or 270 days after the administration; and h) The method of any one of items 1 to 50, wherein the decrease is at a percentage level selected from the group consisting of at least 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% by 90, 180, or 270 days after the administration. (Item 80) After administration of the composition to a human subject requiring treatment for muscular dystrophy, the serum CK level in the subject was compared to the serum CK level before administration of the composition. a) At least 78% within 90, 180, or 270 days after the administration; b) at least 46, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, or 85% within 270 days after the administration; c) at least 72, 73, 74, or 95% within 180 days after the administration; d) at least 87, 88, 93, or 95% within 90 days after the administration; e) at least 70% within 270 days after the administration; f) 70-95% within 90, 180, or 270 days after the administration; g) at least 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% within 90, 180, or 270 days after the administration; and h) The composition according to any one of items 51 to 62, which decreases by at least 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% by 90, 180, or 270 days after the administration. (Item 81) The serum CK level in the subject, compared to the serum CK level before administration of rAAV, after administration of rAAV to the subject, a) At least 78% within 90, 180, or 270 days after the administration; b) At least 46, 55, 56, 57, 58, 59, 6 within 270 days after the administration. 0, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, or 85%; c) at least 72, 73, 74, or 95% within 180 days after the administration; d) at least 87, 88, 93, or 95% within 90 days after the administration; e) at least 70% within 270 days after the administration; f) 70-95% within 90, 180, or 270 days after the administration; g) at least 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% within 90, 180, or 270 days after the administration; and h) Use according to any one of items 63 to 74, which decreases by at least 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% by 90, 180, or 270 days after the administration. (Item 82) a) Nucleotide sequence of Sequence ID No. 3, b) Nucleotide sequence of Sequence ID No. 8, c) Nucleotide sequence of Sequence ID No. 9, d) rAAV containing nucleotides 55-5021 of sequence number 3, e) rAAV containing the nucleic acid sequence of sequence number 9, f) rAAV containing nucleotides 1-4977 of sequence number 8, g) rAAV particles containing nucleotides 55-5021 of sequence number 3, h) rAAV particles containing the nucleic acid sequence of SEQ ID NO: 9, or i) A composition comprising rAAV particles containing nucleotides 1 to 4977 of sequence number 8. [Brief explanation of the drawing]

[0097] [Figure 1] Figure 1 shows the rAAV.MHCK7.microdystrophin construct. In this construct, the cDNA expression cassette is adjacent to the AAV2 reverse terminal repeat sequence (ITR). The construct is characterized by in-frame rod deletions (R4-R23), while hinges 1, 2, and 4 (H1, H2, and H4) and the cysteine-rich domain still produce a 138 kDa protein. Expression of the microdystrophin protein (3579 bp) is induced by the MHCK7 promoter (795 bp). The intron and 5'UTR originate from plasmid pCMVβ (Clontech). The microdystrophin cassette had a small 53 bp synthetic poly(A) signal for common Kosack and mRNA termination immediately before the ATG initiation. As previously described by Harper et al. (Nature Medicine 8, 253-261 (2002)), the human microdystrophin cassette contained (R4-R23 / Δ71-78).

[0098] [Figure 2-1] Figure 2 shows the nucleic acid sequence (SEQ ID NO: 3) AAVrh74.MHCK7.microdystrophin. [Figure 2-2] Same as above. [Figure 2-3] Same as above. [Figure 2-4] Same as above.

[0099] [Figure 3] Figure 3 provides a map of the pNLREP2-Caprh74AAV helper plasmid.

[0100] [Figure 4] Figure 4 shows the Ad helper plasmid pHELP.

[0101] [Figure 5]Figure 5 shows the rAAV.MCK.microdystrophin construct.

[0102] [Figure 6-1] Figure 6 shows the nucleic acid sequence (SEQ ID NO: 5) rAAVrh74.MCK.microdystrophin. [Figure 6-2] Same as above. [Figure 6-3] Same as above. [Figure 6-4] Same as above.

[0103] [Figure 7] Figure 7 shows microdystrophin gene expression in muscle fibers from calf muscle biopsies, as measured by immunocytochemistry.

[0104] [Figure 8-1] Figures 8A–8C provide Western blots showing microdystrophin protein expression at the correct molecular weight. In Figure 8C, sample 4 (*) was diluted 1:4 (in the linear range) as an excess ULDQ (>80%) in the initial analysis, and the mean was multiplied by a dilution correction factor for the final value compared to normal. The mean microdystrophin expression compared to normal was 182.7% in Method 1 and 222.0% in Method 2. [Figure 8-2] Same as above. [Figure 8-3] Same as above.

[0105] [Figure 9-1] Figures 9A-9C show that administration of rAAVrh74.MHCK7.microdystrophin upregulates the expression of DAPC protein, α-sarcoglycan, and β-sarcoglycan. [Figure 9-2] Same as above. [Figure 9-3] Same as above.

[0106] [Figure 10]Figure 10 shows the sustained and dramatic reduction of creatine kinase (CK) levels following administration of rAAVrh74.MHCK7.microdystrophin.

[0107] [Figure 11] Figure 11 shows the mean CK change from baseline to day 270. This data demonstrates a significant decrease in CK over time after administration of rAAVrh74.MHCK7.microdystrophin.

[0108] [Figure 12] Figure 12 shows the mean NSAA and mean CK changes from baseline to day 270. These data showed a significant increase in NSAA over time after rAAVrh74.MHCK7.microdystrophin administration.

[0109] [Figure 13-1] Figure 13 shows the nucleic acid sequence (SEQ ID NO: 9) AAVrh74.MHCK7.microdystrophin. [Figure 13-2] Same as above. [Figure 13-3] Same as above.

[0110] [Figure 14] Figure 14 shows the AAVrh74.MHCK7.microdystrophin plasmid construct.

[0111] [Figure 15-1] Figure 15 provides the nucleic acid sequence (SEQ ID NO: 8) of the AAVrh74.MHCK7.microdystrophin plasmid construct, which contains the kanamycin resistance gene. [Figure 15-2] Same as above. [Figure 15-3] Same as above. [Figure 15-4] Same as above. [Modes for carrying out the invention]

[0112] This invention provides a gene therapy vector, such as an rAAV vector, that overexpresses human microdystrophin, as well as a method for reducing and preventing fibrosis in patients with muscular dystrophy. Muscle biopsies taken at the earliest age of diagnosis of DMD reveal significant connective tissue proliferation. Muscle fibrosis is detrimental in several ways. It reduces the normal passage of intrameningeal nutrients through the connective tissue barrier, reduces blood flow, deprives muscles of nutrients from the blood vessels, and functionally contributes to the early loss of walking ability through limb contractures. Over time, the treatment challenge increases as a result of significant fibrosis in the muscles. This can be observed in muscle biopsies comparing connective tissue proliferation at successive time points. This process continues to worsen, leading to loss of walking ability, and accelerating the loss of control, especially in wheelchair users.

[0113] Without early treatment, including a parallel approach to reduce fibrosis, the benefits of exon skipping, stop-codon read-through, or gene replacement therapy are unlikely to be fully realized. Even small molecule or protein replacement strategies are almost guaranteed to fail without an approach to reduce muscle fibrosis. Previous studies in aged mdx mice with fibrosis treated with AAV. microdystrophin have shown that complete functional recovery could not be achieved (Liu, M. et al., Mol Ther 11, 245-256 (2005)). Progression of DMD cardiomyopathy is also known to be accompanied by ventricular wall scarring and fibrosis.

[0114] As used herein, the term "AAV" is a standard abbreviation for adeno-associated virus. Adeno-associated viruses are single-stranded DNA parvoviruses that grow only in cells, with certain functions provided by co-infecting helper viruses. Currently, there are 13 characterized serotypes of AAV. General information and reviews of AAV can be found, for example, in Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169–228, and Berns, 1990, Virology, pp. 1743–1764, Raven Press, (New York). However, since it is well known that various serotypes are very closely related structurally, functionally, and even at the genetic level, it is quite expected that these same principles are also applicable to additional AAV serotypes. (See, for example, Blacklowe, 1988, 165-174, Parvoviruses and Human Disease, JRPattison (ed.); and Rose, Comprehensive Virology 3:1-61 (1974)). For example, all AAV serotypes clearly exhibit very similar replication characteristics mediated by homologous rep genes, and all give rise to three related capsid proteins, such as those expressed in AAV2. The degree of relevance is further suggested by heteroduplex analysis revealing extensive cross-hybridization between serotypes along genome length, and the presence of similar self-annealing segments at the ends corresponding to “terminal inversion sequences” (ITRs). Similar infectivity patterns suggest that replication function in each serotype is under similar regulatory control.

[0115] As used herein, "AAV vector" refers to a vector containing one or more polynucleotides (or transgenes) of adjacent targets, with an AAV inverted terminal sequence (ITR). Such AAV vectors can be replicated and packaged into infectious viral particles when present in host cells transfected with a vector encoding and expressing rep and cap gene products.

[0116] An "AAV virion," "AAV virus particle," or "AAV vector particle" refers to a viral particle composed of at least one AAV capsid protein and an inclusion polynucleotide AAV vector. If the particle contains heterologous polynucleotides (i.e., polynucleotides other than the wild-type AAV genome, such as a transgene to be delivered to a mammalian cell), it is typically called an "AAV vector particle" or simply an "AAV vector." Thus, the production of an AAV vector particle necessarily involves the production of an AAV vector, and therefore the vector is contained within the AAV vector particle.

[0117] AAV Adeno-associated virus (AAV) is a replication-deficient parvovirus whose single-stranded DNA genome is approximately 4.7 kb long and contains a 145-nucleotide inverted end sequence (ITR). There are multiple serotypes of AAV. The nucleotide sequences of the AAV serotype genomes are known. For example, the nucleotide sequence of the AAV serotype 2 (AAV2) genome was presented in Srivastava et al., J Virol, 45:555-564 (1983), corrected by Ruffing et al., J Gen Virol, 75:3385-3392 (1994). As other examples, the whole genome of AAV-1 is provided to GenBank deposit number NC_002077; the whole genome of AAV-3 is provided to GenBank deposit number NC_1829; the whole genome of AAV-4 is provided to GenBank deposit number NC_001829; the AAV-5 genome is provided to GenBank deposit number AF085716; and the whole genome of AAV-6 is provided to GenBank deposit number NC_00 The genomes were provided in 1862, and at least some of the AAV-7 and AAV-8 genomes are provided to GenBank deposit numbers AX753246 and AX753249, respectively (see also U.S. Patents 7,282,199 and 7,790,449 for AAV-8); the AAV-9 genome is provided to Gao et al., J. Virol., 78:6381-6388 (2004); the AAV-10 genome is provided to Mol. Ther., 13(1):67-76 (2006); and the AAV-11 genome is provided to Virology, 330(2):375-383 (2004). Cloning of the AAVrh.74 serotype is described in Rodino-Klapac et al., Journal of Translational Medicine 5, 45 (2007). The cis-acting sequences that direct viral DNA replication (rep), capsid formation / packaging, and integration into host cell chromosomes are contained within the ITR. Three AAV promoters (named p5, p19, and p40 in relation to their relative map locations) drive the expression of two AAV internal open reading frames that encode the rep and cap genes.Two rep promoters (p5 and p19) bind to different splicings of a single AAV intron (e.g., at AAV2 nucleotides 2107 and 2227), resulting in the production of four rep proteins (rep78, rep68, rep52, and rep40) from the rep gene. The rep proteins possess multiple enzymatic properties ultimately responsible for replicating the viral genome. The cap gene is expressed from the p40 promoter and encodes three capsid proteins: VP1, VP2, and VP3. Alternative splicing and non-consensus translation initiation sites are involved in the production of the three related capsid proteins. A single consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are outlined in Muzyczka, Current Topics in Microbiology and Immunology, 158:97-129 (1992).

[0118] AAV possesses unique characteristics that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is non-cellular, and natural infection in humans and other animals is asymptomatic. Furthermore, because AAV infects many mammalian cells, it can target many different tissues in vivo. Additionally, AAV can transduce slow-dividing and non-dividing cells and, as a transcriptionally active nuclear episome (extrachromosomal element), can essentially persist for the lifespan of these cells. The AAV proviral genome is inserted into a plasmid as cloned DNA, enabling the construction of a recombinant genome. Furthermore, since the signals directing AAV replication, genomic capsid formation, and integration are contained within the ITR of the AAV genome, a portion or all of the approximately 4.3 kb of internal genome (coding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA, such as a gene cassette containing the promoter, target DNA, and polyadenylation signals. The rep and cap proteins may be provided in trans. Another important characteristic of AAV is that it is an extremely stable and viable virus. It readily withstands the conditions used to inactivate adenoviruses (56°C–65°C for several hours), making cold storage of AAV less important. AAV can also be freeze-dried. Finally, AAV-infected cells are not resistant to co-infection.

[0119] Multiple studies have demonstrated long-term (>1.5 years) recombinant AAV-mediated protein expression in muscle. See Clark et al., Hum Gene Ther, 8:659~669 (1997); Kessler et al., Proc Nat. Acad Sc. USA, 93:14082~14087 (1996); and Xiao et al., J Virol, 70:8098~8108 (1996). Also see Chao et al., Mol Ther, 2:619~623 (2000) and Chao et al., Mol Ther, 4:217~222 (2001). Furthermore, because muscles are highly angiogenic, recombinant AAV transduction resulted in the appearance of transgene products in systemic circulation after intramuscular injection, as described by Herzog et al., Proc Natl Acad Sci USA, 94:5804~5809 (1997) and Murphy et al., Proc Natl Acad Sci USA, 94:13921~13926 (1997). In addition, Lewis et al., J Virol, 76:8769~8775 (2002) showed that skeletal muscle fibers possess cellular factors necessary for the correct glycosylation, folding, and secretion of antibodies, indicating that muscles can stably express secreted protein therapeutics.

[0120] The recombinant AAV genome of the present invention comprises the nucleic acid molecule of the present invention and one or more AAV ITRs adjacent to the nucleic acid molecule. The AAV DNA of the rAAV genome may be an AAV serotype that may result from the recombinant virus, which includes, but is not limited to, AAV serotypes AAVrh.74, AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, and AAV-13. The production of pseudotyped rAAV is disclosed, for example, in International Publication No. 01 / 83692. Other types of rAAV variants with capsid mutations, such as rAAV, should also be considered. See, for example, Marsic et al., Molecular Therapy, 22(11):1900-1909 (2014). As mentioned in the background technology section above, the nucleotide sequences of various AAV serotype genomes are known in the art. AAV1, AAV6, AAV8, or AAVrh.74 may be used to promote skeletal muscle-specific expression.

[0121] The DNA plasmid of the present invention comprises the rAAV genome of the present invention. The DNA plasmid is transferred to a cell tolerant of infection with an AAV helper virus (e.g., adenovirus, E1 deletion adenovirus, or herpesvirus), which assembles the rAAV genome into infectious viral particles. Techniques for producing rAAV particles, in which the AAV genome, rep and cap genes, and helper virus function to be packaged are provided to the cell, are standard in the art. The production of rAAV requires that the following components be present in a single cell (indicated herein as a packaging cell): the rAAV genome, the AAVrep and cap genes isolated from (i.e., not present in) the rAAV genome, and the helper virus function. The AAV rep and cap genes may be derived from any AAV serotype, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAVrh.74, AAV-8, AAV-9, AAV-10, AAV-11, AAV-12, and AAV-13, from which the recombinant virus may be derived from and from an AAV serotype different from that of the rAAV genome ITR. The production of pseudotyped rAAV is disclosed, for example, in International Publication No. 01 / 83692, which is incorporated herein by reference in its entirety.

[0122] The method for generating packaging cells involves creating a cell line that stably expresses all the components necessary for AAV particle production. For example, a plasmid (or multiple plasmids) containing a selective marker such as an rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes isolated from the rAAV genome, and a neomycin resistance gene is incorporated into the cell genome. The AAV genome is introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. S6. USA, 79:2077~2081), addition of a synthetic linker containing restriction enzyme endonuclease cleavage sites (Laughlin et al., 1983, Gene, 23:65~73), or direct blunt endligation (Senapathy & Carter, 1984, J. Biol. Chem., 259:4661~4666). The packaging cell line is then infected with a helper virus such as adenovirus. The advantages of this method are that the cells are selectable and it is suitable for large-scale production of rAAV. Another example of a suitable method is to use adenovirus or baculovirus rather than plasmids to introduce the rAAV genome and / or rep and cap genes into packaging cells.

[0123] The general principles of rAAV production are, for example, Carter, 1992, Current Opinions in Biotechnology, pp. 1533-539; and Muzyczka, 1992, Curr. Topics in Microbial. and An overview is provided in Immunol., 158:97-129. Various approaches are described in Ratschin et al., Mol. Cell. Biol., 4:2072 (1984); Hermonat et al., Proc. Natl. Acad. Sci. USA, 81:6466 (1984); Ratschin et al., Mol. Cell. Biol. 5:3251 (1985); McLaughlin et al., J. Virol., 62:1963 (1988); and Lebkowski et al., Mol. Cell. Biol., 7:349 (1988). Samulski et al., J. Virol., 63:3822~3828 (1989); US No. 5,173,414; International Publication No. 95 / 13365 and corresponding US No. 5,658,776; International Publication No. 95 / 13392; International Publication No. 96 / 17947; PCT / US98 / 18600; International Publication No. 97 / 09441 (PCT / US96 / 14423); International Publication No. 97 / 08298 (PCT / US96 / 13872); International Publication No. 97 / 21825 (PCT / US96 / 20777); International Publication No. 97 / 06243 (PCT / FR96 / 01064); International Publication No. 99 / 11764; Perrin et al., Vaccine 13:1244-1250 (1995); Paul et al., Human Gene Therapy 4:609-615 (1993); Clark et al., Gene Therapy 3:1124-1132 (1996); U.S. Patent Nos. 5,786,211; 5,871,982; and 6,258,595. The aforementioned documents are incorporated herein by reference in their entirety, with particular emphasis on these sections of the documents relating to the production of rAAV.

[0124] Therefore, the present invention provides packaging cells that produce infectious rAAV. In one embodiment, the packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (congener 293 strain). In another embodiment, the packaging cells are non-transformed cancer cells such as low-passage 293 cells (human fetal kidney cells transformed with adenovirus E1), MRC-5 cells (human fetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus monkey lung cells).

[0125] The recombinant AAV of the present invention (i.e., infectious capsid-forming rAAV particles) comprises an rAAV genome. In a typical embodiment, the rAAV genome lacks both AAVrep and capDNA, i.e., there are no AAVrep or capDNA between the ITRs of the genome. An example of an rAAV that can be constructed to contain the nucleic acid molecule of the present invention is described in International Patent Application No. PCT / US2012 / 047999 (International Publication No. 2013 / 016352), which is incorporated herein by reference in its entirety.

[0126] In a typical embodiment, the recombinant AAV vector of the present invention is produced by triple transfection using the AAV vector plasmid rAAV.MHCK7.microdystrophin pNLRep2-Caprh74 and pHelp via the ENREF1 method (Xiao et al., J Virol 72, 2224-2232 (1998)), where rAAV contains a microdystrophin gene expression cassette adjacent to the AAV2 inverse terminal sequence (ITR). This is a sequence encapsulated in the AAVrh74 virion. The plasmid contains the microdystrophin sequence, as well as the muscle-specific promoter MHCK7 enhancer and core promoter elements, resulting in gene expression. The expression cassette contains an SV40 intron (SD / SA) to promote high levels of gene expression, and a bovine growth hormone polyadenylation signal is used for efficient transcription termination.

[0127] pNLREP2-Caprh74 is an AAV helper plasmid encoding four wild-type AAV2 rep proteins and three wild-type AAV VP capsid proteins derived from serotype rh74. A schematic diagram of the pNLREP2-Caprh74 plasmid is shown in Figure 3.

[0128] The pHELP adenovirus helper plasmid is 11,635 bp long and was obtained from Applied Viromics. The plasmid contains regions of the adenovirus genome important for AAV replication, namely E2A, E4ORF6, and VA RNA (adenovirus E1 function is provided by 293 cells). The adenovirus sequences present in this plasmid represent only about 40% of the adenovirus genome and do not contain replication-critical cis elements such as adenovirus terminal repeats. Therefore, no infectious adenovirus is present, which would be expected to be produced from such a production system. A schematic map of the pHELP plasmid is shown in Figure 4.

[0129] rAAV may be purified by standard methods in the art, such as column chromatography or a cesium chloride gradient. Methods for purifying rAAV vectors from helper viruses are known in the art and include, for example, the methods disclosed in Clark et al., Hum. Gene Ther., 10(6):1031-1039 (1999); Schenpp and Clark, Methods Mol. Med., 69 427-443 (2002); U.S. Patent No. 6,566,118 and International Publication No. 98 / 09657.

[0130] In another embodiment, the present invention considers compositions comprising the rAAV of the present invention. The compositions of the present invention comprise rAAV and a pharmaceutically acceptable carrier. The compositions may also comprise other components such as diluents and adjuvants. The acceptable carrier, diluents and adjuvants are non-toxic to the recipient, preferably inert at the dosage and concentration used, and include buffers and surfactants such as Pluronics.

[0131] The titer of rAAV to be administered by the method of the present invention may vary depending, for example, on the specific rAAV, the mode of administration, the therapeutic target, the individual, and the cell type(s) targeted, and may be determined by standard methods in the art. The titer of rAAV is approximately 1 × 10⁶ per ml. 6 , about 1×10 7 , about 1×10 8 , about 1×10 9 , about 1×10 10 , about 1×10 11 , about 1×10 12 , about 1×10 13 ~Approx. 1×10 14 Or it may be in the range of DNase-resistant particles (DRPs) or higher. The dosage may also be expressed in units of viral genome (vg). One exemplary method for determining the capsid-forming vector genome titer is to use quantitative PCR, such as the method described in (Pozsgai et al., Mol.Ther.25(4):855~869, 2017).

[0132] Methods for transducing target cells with rAAV in vivo or in vitro are considered in the present invention. An in vivo method comprises administering an effective dose, or effective repeated dose, of a composition comprising rAAV of the present invention to an animal (including humans) in need of it. If the dose is administered before the onset of the disorder / disease, the administration is prophylactic. If the dose is administered after the onset of the disorder / disease, the administration is therapeutic. In embodiments of the present invention, an effective dose is a dose that alleviates (eliminates or reduces) at least one symptom associated with the disorder / disease being treated, delays or prevents progression to the disorder / disease state, delays or prevents progression of the disorder / disease condition, reduces the severity of the disease, results in remission (partial or complete) of the disease, and / or prolongs survival. An example of a disease intended for prevention or treatment by the methods of the present invention is DMD.

[0133] Combination therapies are also considered in this invention. The combinations used herein include both concurrent and sequential therapies. Combinations of the methods of this invention with standard medical procedures (e.g., corticosteroids) are given particular consideration, as are combinations with novel therapies.

[0134] The effective dose of the composition may be administered by standard routes in the art, including, but not limited to, intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or vaginal. The route(s) and serotype(s) of the AAV components of rAAV (in particular AAV ITR and capsid protein) may be selected and / or adapted by those skilled in the art, taking into account the infection and / or disease state being treated, as well as the target cells / tissues(s) that will express microdystrophin.

[0135] The present invention provides topical and systemic administration of effective doses of rAAV and compositions of the present invention. For example, systemic administration is administration to the circulatory system that affects the whole body. Systemic administration includes absorption via the gastrointestinal tract and enteral administration such as parenteral administration via injection, infusion, or transplantation.

[0136] In particular, the practical administration of rAAV according to the present invention can be achieved using any physical method for transporting the recombinant rAAV vector to the target tissue of an animal. Administration according to the present invention includes, but is not limited to, intramuscular injection and injection into the bloodstream. It has been shown that simply resuspending rAAV in phosphate-buffered saline is sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on the carrier or other components that can be co-administered with rAAV (although DNA-degrading compositions should be avoided in conventional methods using rAAV). The capsid protein of rAAV may be modified so that rAAV targets a specific target tissue of the subject, such as muscle. See, for example, International Publication No. 02 / 053703, the disclosure of which is incorporated herein by reference. The pharmaceutical composition can be prepared as an injectable formulation or a topical formulation to be delivered to muscle by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and can be used in the practice of the present invention. rAAV can be used with any pharmaceutically acceptable carrier to facilitate administration and handling.

[0137] In one embodiment of the present invention, the AAVrh74.MHCK7.microdystrophin described herein is formulated in a buffer containing 20 mM Tris (pH 8.0), 1 mM magnesium chloride (MgCl2), 200 mM sodium chloride (NaCl), and 0.001% poloxamer 188.

[0138] The dose of rAAV to be administered by the methods disclosed herein may vary depending, for example, on the specific rAAV, mode of administration, therapeutic goal, individual, and targeted cell type(s), and may be determined by methods standard in the art. The titer of each rAAV administered is approximately 1 × 10⁶ per ml. 6 , about 1×10 7 , about 1×10 8 , about 1×10 9 , about 1×10 10 , about 1×10 11 , about 1×10 12 , about 1×1013 , about 1×10 14 , about 2×10 14 , or ~approximately 1 x 10 15 Or it may be in the range of DNase-resistant particles (DRPs) or higher. The dosage may also be expressed in units of viral genome (vg) (i.e., 1 × 10⁻⁶ each). 7 vg, 1×10 8 vg, 1×10 9 vg, 1×10 10 vg, 1×10 11 vg, 1×10 12 vg, 1×10 13 vg, 1×10 14 vg, 2×10 14 vg, 1×10 15 The dosage may be expressed in units of viral genomes (vg) per kilogram (kg) of body weight (i.e., 1 × 10⁻¹⁶). 10 vg / kg, 1 × 10 11 vg / kg, 1 × 10 12 vg / kg, 1 × 10 13 vg / kg, 1 × 10 14 vg / kg, 1.25 × 10 14 vg / kg, 1.5 × 10 14 vg / kg, 1.75 × 10 14 vg / kg, 2.0 × 10 14 vg / kg, 2.25 × 10 14 vg / kg, 2.5 × 10 14 vg / kg, 2.75 × 10 14 vg / kg, 3.0 × 10 14 vg / kg, 3.25 × 10 14 vg / kg, 3.5 × 10 14 vg / kg, 3.75 × 10 14 vg / kg, 4.0 × 10 14 vg / kg, 1 × 10 15 (vg / kg). The method for determining the titer of an AAV is described in Clark et al., Hum. Gene Ther., 10:1031-1039 (1999).

[0139] In particular, the actual administration of rAAV according to the present invention can be achieved using any physical method for transporting the rAAV recombinant vector to the target tissue of an animal. Administration according to the present invention includes, but is not limited to, intramuscular injection and injection into the bloodstream. It has been shown that simply resuspending rAAV in phosphate-buffered saline is sufficient to provide a vehicle useful for muscle tissue expression, and there are no known limitations on the carrier or other components that can be co-administered with rAAV (although DNA-degrading compositions should be avoided in conventional methods using rAAV). The capsid protein of rAAV may be modified so that rAAV targets a specific target tissue of the subject, such as muscle. See, for example, International Publication No. 02 / 053703, the disclosure of which is incorporated herein by reference. The pharmaceutical composition can be prepared as an injectable formulation or a topical formulation to be delivered to muscle by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and can be used in the practice of the present invention. rAAV can be used with any pharmaceutically acceptable carrier to facilitate administration and handling.

[0140] For intramuscular injection, solutions in adjuvants such as sesame oil or peanut oil, aqueous solutions of propylene glycol, and sterile aqueous solutions can be used. Such aqueous solutions can be buffered if desired, and the liquid diluent can be isotonic first with physiological saline or glucose. rAAV solutions as free acids (DNA contains acidic phosphate groups) or pharmaceutically acceptable salts can be prepared in water appropriately mixed with a surfactant such as hydroxypropylcellulose. Dispersions of rAAV can also be prepared in glycerol, liquid polyethylene glycol and mixtures thereof, and oils. Under normal storage and use conditions, these preparations contain preservatives to prevent microbial growth. In this regard, all sterile aqueous media used are readily available by standard techniques well known to those skilled in the art.

[0141] Pharmaceutical carriers, diluents, or excipients suitable for injectable use include sterile aqueous solutions or dispersions, and sterile powders for the immediate preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and fluid enough to be readily injectable. It must be stable under manufacturing and storage conditions and preserved against microbial contamination such as bacteria and fungi. Carriers may be solvents or dispersion media containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. Adequate fluidity can be maintained, for example, by the use of coating agents such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. Prevention of microbial action can be provided by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. Often, it is preferable to include isotonic agents, such as sugars or sodium chloride. Sustained absorption of injectable compositions can be achieved by using absorption-delaying agents, such as aluminum monostearate and gelatin.

[0142] Sterile injectable solutions are prepared by incorporating the required amount of rAAV in a suitable solvent along with various other components listed above, and then, if necessary, by filter sterilization. Generally, dispersions are prepared by incorporating a sterile active ingredient into a sterile medium containing a basic dispersion medium and other components required from those listed above. For sterile powders for the preparation of sterile injectable solutions, preferred preparation methods include vacuum drying and freeze-drying techniques to produce a powder of the active ingredient and any additional desired components from its already filter-sterilized solution.

[0143] Transduction using rAAV can also be performed in vitro. In one embodiment, desired target muscle cells are isolated from the target, transduced with rAAV, and reintroduced into the target. Alternatively, syngeneic or heterogeneic muscle cells can be used if these cells do not produce an inappropriate immune response in the target.

[0144] Suitable methods for transduction and re-transduction of transduced cells into a target are known in the art. In one embodiment, cells can be transduced in vitro, for example, by combining rAAV with muscle cells in a suitable culture medium and screening those cells for the target DNA using conventional techniques such as Southern blotting and / or PCR, or using a selection marker. The transduced cells are then formulated into a pharmaceutical composition, which can be introduced into a target by various techniques such as intramuscular, intravenous, subcutaneous and intraperitoneal injection, or injection into smooth muscle and cardiac muscle using, for example, a catheter.

[0145] Transduction of cells using the rAAV of the present invention results in sustained expression of the microdystrophin protein. Therefore, the present invention provides a method for administering / delivering rAAV expressing the microdystrophin protein to animals, preferably humans. These methods involve transducing tissues (including, but not limited to, muscle-like tissues, organs such as the liver and brain, and glands such as salivary glands) using one or more rAAVs of the present invention. Transduction may be carried out using a gene cassette containing tissue-specific regulatory elements. For example, one embodiment of the present invention is derived from actin and myosin gene families such as the myoD gene family (see Weintraub et al., Science, 251:761~766 (1991)), muscle cell-specific enhancer binding factor MEF-2 (Cserjesi and Olson, Mol Cell Biol 11:4854~4862 (1991)), regulatory elements derived from human skeletal actin genes (Muscat et al., Mol Cell Biol, 7:4089~4099 (1987)), cardiac actin genes, muscle creatine kinase sequence elements (Johnson et al., Mol Cell Biol, 9:3393~3399 (1989)), and mouse creatine kinase enhancer (mCK) elements, regulatory elements derived from the skeletal fast contractile troponin C gene, slow contractile cardiac troponin C gene, and slow contractile troponin I gene: hypoxia-induced nuclear factor (Semenza et al., Proc The present invention provides a method for transducing muscle cells and muscle tissue by muscle-specific regulatory elements, including, but not limited to, steroid-induced elements and promoters containing glucocorticoid response elements (GREs) (see Mader and White, Proc. Natl. Acad. Sci. USA 90:5603~5607 (1993)), as well as other regulatory elements.

[0146] Muscle tissue is an attractive target for in vivo DNA delivery because it is not a vital organ and is easily accessible. This invention considers the sustained expression of microdystrophin from transduced muscle fibers.

[0147] "Muscle cells" or "muscle tissue" means cells or groups of cells derived from any type of muscle (e.g., skeletal muscle and smooth muscle, e.g., gastrointestinal tract, bladder, blood vessels, or cardiac tissue). Such muscle cells may be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes, and cardiomyocytes.

[0148] The term "transduction" is used to refer to the administration / delivery of the microdystrophin coding region to recipient cells via the replication-deficient rAAV of the present invention, either in vivo or in vitro, resulting in the expression of microdystrophin by the recipient cells.

[0149] Therefore, the present invention provides a method for administering an effective amount of rAAV encoding microdystrophin (or a dose administered essentially simultaneously or at regular intervals) to a subject in need of it.

[0150] The following examples are provided for illustrative purposes only and are not limiting. The numerical ranges described include each integer value within each range, including the minimum and maximum specified integers. [Examples]

[0151] Example 1 A) Generation of AAVrh74.MHCK7.microdystrophin construct The AAVrh74.MHCK7.microdystrophin plasmid contains a human microdystrophin cDNA expression cassette flanked by the AAV2 inverted terminal repeat (ITR) (see Figure 1). The microdystrophin construct is characterized by in-frame rod deletions (R4-R23), while hinges 1, 2, and 4, as well as cysteine-rich domains, still produce a 138 kDa protein. Expression of the microdystrophin protein (3579 bp) was induced by the MHCK7 promoter (792 bp). The plasmid was constructed from the rAAV.MCK.microdystrophin plasmid by removing the MCK promoter and inserting the MHCK7 promoter. Following the core promoter, a 53 bp endogenous mouse MCK exon 1 (untranslated) is present for efficient transcription initiation, followed by the SV40 late 16S / 19S splice signal (150 bp) and a small 5'UTR (61 bp). The introns and 5'UTR are derived from plasmid pCMVβ (Clontech). The microdystrophin cassette had a small 53 bp synthetic polyA signal for common cossack and mRNA termination immediately before the ATG start. The human microdystrophin cassette contained (R4~R23 / Δ71~78), as previously described by Harper et al. (Nature Medicine 8, 253~261 (2002)). The complementary DNA was a codon optimized for human use and synthesized by GenScript (Piscataway, New Jersey) (Mol Ther 18, 109~117 (2010)). The only viral sequence included in this vector is the inverted terminal repeat sequence of AAV2, which is required for both viral DNA replication and packaging. The microdystrophin cassette has a small 53 bp synthetic polyA signal for mRNA termination.

[0152] Previous studies have demonstrated cardiac expression using the MHCK7 promoter (Salva et al., Mol Ther 15, 320-329 (2007)), and AAVrh74 achieving skeletal muscle, diaphragmatic muscle, and cardiac muscle expression (Sondergaard et al., Annals of Clinical and Transl Neurology 2, 256-270 (2015)), and the construct sequence shown in Figure 1 was encapsulated in AAVrh.74 virions. Molecular clones of the AAVrh.74 serotype were cloned from rhesus monkey lymph nodes and discussed in Rodino-Klapac et al., Journal of Translational Medicine 5, 45 (2007). Table 1 shows the molecular properties of plasmid AAVrh74.MHCK7.microdystrophin (SEQ ID NO: 3). [Table 1]

[0153] B) AAVrh74.MHCK7. Generation from a plasmid encoding kanamycin (Kan) resistance of the microdystrophin construct and plasmid encoding kanamycin (Kan) resistance Cloning of MHCK7.μDys.KAN was achieved by isolating MHCK7.μDys fragments from the MHCK7.μDys.AMP plasmid and kanamycin backbone, and then annealing them using the NEBuilder cloning workflow. MHCK7.μDys fragments were isolated via restriction enzyme digestion using SnaBI. Digestion was performed at 37°C for 1 hour in 50 μL of total reaction mixture in 1×CutSmart Buffer (NEB) and 1 μL of SnaBI. The resulting fragments were isolated by electrophoresis using a 1% agarose gel, run at 105 volts for 1.5 hours. The band corresponding to the MHCK7.μDys insert was excised and purified using a gel purification kit (Macherey-Nagel). The resulting fragments had a DNA concentration of 10 ng / μL. Kan backbone fragments were isolated by XbaI restriction enzyme digestion in 50 μL of a reaction mixture containing 1 × CutSmart buffer (NEB) and 1 μL of XbaI at 37°C for 1 hour. The resulting fragments were isolated by electrophoresis using a 1% agarose gel, run at 105 volts for 1.5 hours. The band corresponding to the Kan backbone was excised and purified using a gel purification kit (Macherey-Nagel). The resulting fragments had a DNA concentration of 8.1 ng / μL. The two fragments were annealed using the NEB Builder cloning workflow, which has the ability to join two fragments at a duplicated sequence. The NEBuilder cloning reaction was performed according to the manufacturer's protocol at 50°C for 15 minutes, using a total reaction volume of 20 μL of 1 × NEBuilder HiFi DNA Assembly Master Mix with a MHCK 7 μDys ratio of 1:1 to the kanamycin backbone. The obtained clones were transformed into NEB® stable competent Escherichia coli (C3040) by adding 2.5 L of the cloning product to cells, followed by 30 minutes on ice, then 30 seconds at 42°C, and a further 5 minutes on ice. After transformation, 950 μL of growth medium was added to the cells, and the cells were grown at 30°C for 1.5 hours with shaking at 225 rpm.After proliferation, 450 μL of these cells were seeded onto 50 μg / mL kanamycin LB agar plates and incubated overnight at 30°C in a dry incubator. Colonies were picked from these plates and grown overnight in LB containing 50 μg / mL kanamycin. DNA was isolated from 3 mL of this culture using the QIAprep® Spin Miniprep Kit (Qiagen). This DNA was used to confirm the cloning product. The cloning product was confirmed by restriction enzyme digestion using PmeI, MscI, and SmaI, followed by gel electrophoresis. The cloning product was further confirmed by sequencing. The resulting plasmid is described in Sequence ID No. 8 and is shown in Figures 14 and 15. The sequence of the construct in Figure 13 corresponding to Sequence ID No. 9, and nucleotides 1-4977 of Sequence ID No. 8, were encapsulated in AAVrh.74 virions as described above.

[0154] Example 2 Clinical trial of systemic gene delivery for Duchenne muscular dystrophy This is a single-dose controlled study using microdystrophin (SEQ ID NO: 3, nucleotides 55-5021, rAAVrh74.MHCK7.) for DMD subjects. Cohort A includes 6 subjects aged 3 months to 3 years, and Cohort B includes 6 subjects aged 4 to 7 years. All subjects received intravenous administration of the microdystrophin vector (2 × 10⁶ mL / kg). 14 (vg / kg). Microdystrophin is formulated in a buffer containing 20 mM Tris (pH 8.0), 1 mM magnesium chloride (MgCl2), 200 mM sodium chloride (NaCl), and 0.001% poloxamer 188.

[0155] In the study, rAAVrh74.MHCK7.microdystrophin was injected via peripheral brachial vein to reach all muscles in the body. Cohort A enrolled 6 DMD patients aged 3 months to 3 years, and Cohort B enrolled 6 DMD patients aged 4 to 7 years. All subjects received intravenous administration of the microdystrophin vector (2 × 10⁶ mL / kg).14 (vg / kg). The encapsulated vector genome for the administered dose was determined by quantitative PCR using a Prism 7500 Taqman detector system (PE Applied Biosystems) with primers for the MHCK7 promoter, compared to a supercoiled DNA plasmid standard (Pozsgai et al., Mol.Ther.25(4):855~869, 2017).

[0156] Participants received intravenous infusion over one hour in the pediatric intensive care unit (PICU) at Nationwide Children's Hospital. A muscle biopsy was performed during the screening visit prior to gene therapy. Participants underwent a second muscle biopsy 90 days after delivery to determine if replacement of the deficient dystrophin protein was possible. After gene delivery, patients were carefully monitored for treatment side effects. This monitoring included blood and urine tests, as well as physical examinations, during the screening visit and at days 0, 1, 7, 14, 30, 60, 90, and 180, and at months 9, 12, 18, 24, 30, and 36, to ensure that no side effects originating from the gene injection were present.

[0157] Cohort A (n=6) consisted of children aged 3 months to 3 years who received intravenous administration of rAAVrh74.MHCK7.microdystrophin vector (2 × 10 mL / kg). 14 (vg / kg). In Cohort A, subjects were initiated with 1 mg / kg prednisone or deflazacort one day prior to gene transfer and managed for 30 days while monitoring their immune response. If negative on day 30, steroids were gradually discontinued over one week. If the T cell response to AAV or MicroDICE was >125 SFC / 106 PBMC, steroids were maintained until the level fell below this threshold.

[0158] The subjects in Cohort B (n=6) were 4 to 7 years old and received intravenous administration of rAAVrh74.MHCK7.microdystrophin vector (2 × 10 mL / kg). 14(vg / kg). These subjects were managed with stable doses of corticosteroids throughout the clinical trial, but if the T cell response to AAV or microdystrophin was >125 SFC / 106 PBMC, a short-term dose increase was permitted.

[0159] Eligibility Criteria The selection criteria for the clinical trial were as follows: • Registered age: Cohort A: 3 months to 7 years, Cohort B: 4 to 7 years (including the age range). • Molecular characteristics of the DMD gene with frameshift (deletion or duplication) or immature stop codon mutations in exons 18-58. • CK increase > 1000 U / L • Cohort A subjects: Below average on the Bayley-III motor assessment for macroscopic movement, defined as an adjusted score of ≤9. • Cohort B: Defined as having a predicted value <80%, with a below-average time test performance in the 100-meter test. • A male of any ethnicity. • Ability to cooperate in physical assessment tests. • Cohort A subjects: No prior history of corticosteroid treatment. • Cohort B subjects: Oral corticosteroids equivalent to a stable dose for at least 12 weeks prior to screening; the dose is expected to remain constant throughout the study period (except for adjustments to accommodate changes in body weight).

[0160] The exclusion criteria for this clinical trial were as follows: • Active viral infection based on clinical findings. • Signs of cardiomyopathy, including echocardiography showing an ejection fraction of less than 40%. Serological evidence of HIV infection or hepatitis B or C infection. • Diagnosis (or ongoing treatment) of an autoimmune disease. • Abnormal laboratory values ​​that are considered clinically significant. • The need for chronic drug treatment that poses an unnecessary risk to gene transfer in the context of co-existing diseases or PIs. Subjects with AAVrh74 or AAV8 antibody titer >1:400, as determined by ELISA immunoassay. • In the investigator's view, any medical condition or mitigating circumstances that could jeopardize the subject's ability to comply with the protocol or method, or jeopardize the subject's health, safety, or clinically explainable capacity. • Severe infection (e.g., pneumonia, renal venous nephritis, or meningitis) within 4 weeks prior to the gene transfer appointment (registration may be postponed). • In the six months prior to screening for this clinical trial, participants received experimental or reverse administration of investigational drugs (other than corticosteroids) or exon skipping drugs (including ExonDys 51®). • Received any type of gene therapy, cell-based therapy (e.g., stem cell transplantation), or CRISPR / Cas9 therapy. • The family does not wish to disclose the patient's participation in the clinical trial to their primary care physician or other healthcare providers.

[0161] Evaluation items The primary endpoint was safety based on the number of participants experiencing adverse events (timeframe: 3 years). Adverse events were monitored and scored for severity and association with research publications.

[0162] The secondary evaluation items were as follows:

[0163] Gross Motor Subtest Measurement (Bayley-III) Score (Timeframe: Screening, Day 30–3 Years): Gross motor scale scores measured motor development. The Bayley-III Gross Motor Subtest was scored for Cohort A at all follow-up visits, starting at Day 30 and continuing until Year 3. Any subject aged 43–47 months (including age) at screening had a scaled score calculated compared to standard data for 42-month-old children. Bayley-III provides standard data for children aged 1–42 months.

[0164] Physical therapy assessment. 100-meter timed test (100m) (Time frame: screening, day 30 to 3 years): The 100m was the primary exercise outcome in Cohort B. The 100-meter timed test was a study initiated in Cohort A when children reached 3 years of age.

[0165] Physical therapy assessment. Northstar Gait Assessment (NSAA) (Time frame: Screening, Day 30 to 3 years): The Northstar Gait Assessment (NSAA) was a study initiated at age 4 for cohort A and cohort B. The NSAA measures the quality of gait in young boys with Duchenne muscular dystrophy.

[0166] Physical therapy assessment in children using the Timed Up and Go (TUG) test (time frame: screening, day 30 to 3 years): The results for Cohort B included a modified Timed Up and Go (TUG) test for children.

[0167] Four-level increases and decreases in physical therapy assessment (timeframe: screening, day 30 to 3 years): The findings for Cohort B include four levels of increases and decreases.

[0168] Handheld strength measurement (HHD) for physical therapy assessment (time frame: screening, day 30 to 3 years): The results for Cohort B included handheld strength measurement (HHD) of the knee extensor and flexor muscles, as well as the elbow flexor and extensor muscles.

[0169] Quantitative determination of microdystrophin gene expression by immunofluorescence staining (time frame: screening, day 90): Microdystrophin gene expression levels were quantified by immunofluorescence staining and compared before and after muscle biopsy.

[0170] Quantitative determination of microdystrophin gene expression by immunofluorescence staining (time frame: screening, day 90): Microdystrophin gene expression levels were quantified by Western blotting and compared before and after muscle biopsy.

[0171] Decrease in CK levels after gene therapy (timeframe: 3 years): Decrease in circulating blood CK levels.

[0172] Cardiac magnetic resonance imaging (at 1 year).

[0173] Microdystrophin gene expression The change from baseline in microdystrophin expression via immunofluorescence (IF) fiber intensity was analyzed and quantified. As shown in Figure 7, Subject 1 (5 years old) showed 78% microdystrophin protein expression in muscle fibers from calf muscle biopsy after administration of rAAVrh74.MHCK7.microdystrophin, Subject 2 (4 years old) showed 73.5% microdystrophin protein expression in muscle fibers from calf muscle biopsy after administration of rAAVrh74.MHCK7.microdystrophin, and Subject 3 (6 years old) showed 77.0% microdystrophin protein expression in muscle fibers from calf muscle biopsy after administration of rAAVrh74.MHCK7.microdystrophin. Subject 4 (4 years old) showed 96.2% microdystrophin expression in muscle fibers from calf muscle biopsy after administration of rAAVrh74.MHCK7.microdystrophin. All patients showed potent expression of transduced microdystrophin, which localized appropriately in the muscle sheath as measured by immunohistochemistry. The mean gene expression, measured by the percentage of microdystrophin-positive fibers, was 76.2%, and the mean fiber strength was 74.5% compared to normal controls. [Table 7-1] [Table 7-2]

[0174] Changes in microdystrophin gene expression from baseline to day 60 were also evaluated by quantifying microdystrophin protein expression measured by Western blotting of biopsied muscle tissue. As shown in Figures 8A and 8B, Western blotting analysis detected microdystrophin protein expression in subjects 1 (5 years old), 2 (4 years old), and 3 (6 years old). Figure 8C provides a Western blotting analysis detecting microdystrophin protein expression in subject 4 (4 years old). All post-treatment biopsies showed healthy levels of microdystrophin as measured by Western blotting, which was 74.3% of normal for subjects 1–4 using Method 1, and 95.8% of normal for subjects 1–4 according to Method 2, which was adjusted for adipose and fibrous tissues.

[0175] For each subject, the number of vector genome copies per muscle fiber nucleus was measured. As shown in Table 2, the number of vector genome copies per nuclease was greater than 1 for each subject after administration of rAAVrh74, MHCK7, and microdystrophin. One copy of the vector represents approximately 50% expression of the microdystrophin gene. An average of 1.6 vector copies per cell nucleus was measured in subjects 1-3, which was consistent with the observed high microdystrophin expression levels. Including the value for subject 4, the average vector copies / 1 μg of DNA was >10 5 There were an average of 3.3 vector copies per cell nucleus. [Table 2]

[0176] Protein levels of α-sarcoglycans and β-sarcoglycans in muscle biopsy tissue were measured by immunohistochemistry before and after administration of rAAVrh74.MHCK7.microdystrophin. Administration of rAAVrh74.MHCK7 also resulted in upregulation of DAPC protein in the subjects. As shown in Figure 9, the expression of α-sarcoglycans and β-sarcoglycans in muscle biopsy tissue was increased compared to the levels of these proteins in muscle biopsies before rAAVrh74.MHCK7 administration in subjects 1 (Figure 9A), 2 (Figure 9B), and 3 (Figure 9C). Circulating serum CK levels

[0177] Blood sample, rAAVrh74.MHCK7.microdystrophin vector (2 × 10 in 10 mL / kg) 14 Samples were collected every 30 days after intravenous infusion of vg / kg. CK levels were measured at each visit and compared to baseline levels obtained before administration of rAAVrh74.MHCK7.microdystrophin (day 0 of visit). Baseline serum CK levels (units / liter) are provided in Table 3 below. As shown in Figure 10, circulating serum CK levels decreased by approximately 87% two months after administration of rAAVrh74.MHCK7.microdystrophin. All subjects showed a significant decrease in serum creatine kinase (CK) levels, which was accompanied by a mean decrease of over 87% in CK two months after treatment (n=3). CK is an enzyme associated with muscle damage, and patients with DMD consistently show high levels of CK. In fact, significantly elevated CK is often used as a preliminary diagnostic tool for DMD, followed by definitive genetic testing.

[0178] Table 4 and Figure 10 provide CK levels for each subject. Figure 11 provides mean CK levels over time, showing a significant decrease in mean CK levels over time after administration of rAAVrh74.MHCK7.microdystrophin. The mean baseline CK level of 27,064 U / L (mean in Table 3) decreased by approximately 63% to a mean of 9,982 U / L (mean, day 270, Table 4). [Table 3] [Table 4]

[0179] Effectiveness evaluation In addition to microdystrophin and CK levels, efficacy was measured by the following functional tests: time to stand up from the floor, time to climb four stairs, Northstar gait assessment (NSAA), time to stand test, time to climb four stairs, 10-meter timed test (10m), and 100-meter timed test (100m). The data are provided in Tables 5 and 6 below, and these data show consistent and sustained improvement 9 months after administration of rAAVrh74.MHCK7. Improved NSAA over time is also provided in Figure 12. [Table 5-1] [Table 5-2] [Table 6]

[0180] Safety evaluation No serious adverse events (SAEs) were observed during the study. Three subjects had elevated gamma-glutamyltransferase (GGT) levels, which resolved within one week with increased steroids and returned to baseline levels. No other clinically significant laboratory findings were present. Patients generally experienced transient nausea during the first week of therapy, coinciding with increased steroid dosage. This was not correlated with elevated liver enzymes or any other abnormalities.

[0181] Example 3 Randomized, double-blind, placebo-controlled phase I / IIa clinical trial of systemic gene delivery This is a randomized, double-blind, single-dose trial using rAAVrh74.MHCK7.microdystrophin in patients with DMD. The trial includes 24 participants aged 4–7 years. Participants were randomized to receive either treatment or placebo at enrollment. Twelve participants received intravenous administration of the rAAVrh74.MHCK7.microdystrophin vector (approximately 10 mL / kg at 2 × 10⁶ times). 14 Twelve subjects will be administered 10 mL / kg placebo (lactated Ringer's solution) (vg / kg). The placebo subjects will proceed to treatment one year after the last subject was treated, using the same method as the 12 subjects who were already treated. Subjects will be injected with rAAV containing microdystrophin or lactated Ringer's solution over approximately one hour. Needle muscle biopsies will be performed in the gastrocnemius muscle before and after treatment (90 days later).

[0182] The primary objective of this study is to evaluate the safety of intravenous administration of rAAVrh74.MHCK7.microdystrophin via peripheral extremity veins to patients with DMD. Safety endpoints will be assessed by hematological tests, blood biochemistry tests, changes in urinalysis, immune responses to rAAVrh74 and microdystrophin, and observation of reported medical history and symptoms. Dystrophin gene expression will serve as a primary outcome measure along with safety. Quantification will be performed using validated immunofluorescence and immunoblot assays. A decrease in CK after gene therapy will serve as a secondary outcome. Efficacy will be measured by the following functional tests: time to stand, time to climb four stairs, Northstar gait assessment (NSAA), 10-meter timed test (10m), and 100-meter timed test (100m). Survey measurements will include handheld strength testing (HHD) of the knee extensor and flexor muscles, as well as the elbow flexor and extensor muscles.

[0183] The selection criteria for this study are as follows: • Registered age: 4-7 years old (including age). • Molecular characteristics of the DMD gene with frameshift (deletion or duplication) or immature stop codon mutations in exons 18-58. • Signs of symptomatic muscular dystrophy: elevated CK > 1000 U / L and less than the mean percent predicted time on the 100-meter walking test. Men from any ethnic group are eligible. • Ability to cooperate in physical assessment tests. • Oral corticosteroids equivalent to a stable dose for at least 12 weeks prior to screening; the dose is expected to remain constant throughout the study period (except for possible adjustments to accommodate weight changes).

[0184] The exclusion criteria for this clinical trial are as follows: • Active viral infection based on clinical findings. • Signs of cardiomyopathy, including echocardiography showing an ejection fraction of less than 40%. Serological evidence of HIV infection or hepatitis B or C infection. • Diagnosis (or ongoing treatment) of an autoimmune disease. • Clinically significant abnormal clinical laboratory values ​​(GGT > 3XULN, bilirubin ≥ 3.0 mg / dL, creatinine ≥ 1.8 mg / dL, Hgb < 8 or > 18 g / dL, WBC > 18,500 per 1 cmm), platelets ≤ 50,000. • The need for chronic drug treatment that poses an unnecessary risk to gene transfer in the context of co-existing diseases or PIs. Subjects with an AAVrh74 or AAV8 antibody titer >1:400, as determined by ELISA immunoassay. If the endpoint titer is positive at screening, testing may be repeated before exclusion. In the investigator's view, there is a medical condition or extenuating circumstances that could jeopardize the subject's ability to comply with the protocol or method, or jeopardize the subject's health, safety, or clinically explainable capacity. • Severe infection (e.g., pneumonia, renal venous nephritis, or meningitis) within 4 weeks prior to the gene transfer appointment (registration may be postponed). • In the six months prior to screening for this clinical trial, participants received experimental or reverse administration of investigational drugs (other than corticosteroids) or exon skipping drugs (including ExonDys 51®). • Received any type of gene therapy, cell-based therapy (e.g., stem cell transplantation), or CRISPR / Cas9 therapy. • The family does not wish to disclose the patient's participation in the clinical trial to their primary care physician or other healthcare providers.

[0185] Effectiveness evaluation Dystrophin gene expression serves as a primary outcome measure, along with safety. Quantification is performed using validated immunofluorescence and immunoblot assays. A decrease in CK after gene therapy serves as a secondary outcome. In addition, efficacy is measured by the following functional tests: time to stand up from the floor, time to climb four stairs, Northstar gait assessment (NSAA), 10-meter timed test (10m), and 100-meter timed test (100m). Survey measurements include handheld strength testing (HHD) of the knee extensor and flexor muscles, as well as the elbow flexor and extensor muscles.

[0186] Transgene expression will be quantified by comparing baseline and day 90 using ultrasound-guided muscle biopsies. Biopsies will be performed from the same muscle as the original biopsy, but from the opposite leg. One year after administration to all subjects, placebo crossover subjects will resume the trial schedule at their first visit. Placebo subjects will not undergo the following at their second baseline screening: cardiac MRI and muscle biopsy. Placebo subjects will undergo a muscle biopsy at day 90 (a total of three muscle biopsies). Frozen sections will be stained for dystrophin using indirect immunofluorescence (IF). Complete slide scans will be performed, and microdystrophin intensity and the percentage of positive fibers will be quantified using validated image scans and the MuscleMap® analysis algorithm. Muscle morphometry, including fiber size histograms, will be performed blindly. Quantitative protein analysis for microdystrophin will be performed using a validated Western blotting method with blinded frozen muscle biopsy shavings.

[0187] Microdystrophin expression is quantified using a muscle needle biopsy of the gastrocnemius muscle (unless PI is contraindicated in a specific subject, in which case PI will be performed by selecting a different muscle for biopsy).

[0188] Efficacy analysis The primary efficacy endpoint is the change in microdystrophin protein expression levels from baseline to day 90, as measured by Western blotting of biopsied muscle tissue. Treatment-group differences for the primary efficacy endpoint are assessed using an analysis of covariance (ANCOVA) model with treatment as a fixed factor and baseline values ​​as covariates. Wilcoxon's rank-sum test is performed as a supplementary analysis. Changes in microdystrophin expression from baseline are similarly analyzed via immunofluorescence (IF) fiber intensity.

[0189] Supplemental efficacy endpoints include changes from baseline to each scheduled assessment in time to stand from the floor, time to climb four steps, NSAA, 10-meter timed test (10m), 100-meter timed test (100m), and changes in CK. Survey measurements include HHD for knee extensor and flexor muscles, as well as elbow flexor and extensor muscles. Treatment group differences are assessed using an ANCOVA model with treatment as a fixed factor and baseline values ​​as covariates. Wilcoxon rank-sum tests are performed as supplemental analyses.

[0190] Example 4 The tests and studies described in Examples 2 and 3 above may be carried out instead using the rAAVrh74.MHCK7.microdystrophin construct described in SEQ ID NO: 9, SEQ ID NO: 8, nucleotides 1-4977, or SEQ ID NO: 6, nucleotides 56-5022.

[0191] Example 5 Generation of pAAV.MCK.microdystrophin construct The pAAV.MCK.microdystrophin plasmid was constructed by inserting an MCK expression cassette yielding a codon-optimized human microdystrophin cDNA sequence into the AAV cloning vector psub201 (Samulski et al., J. Virol. 61(10):3096~3101). A muscle-specific regulatory element was included in the construct, resulting in muscle-specific gene expression. This regulatory element contained a mouse MCK core enhancer (206 bp) fused to a 351 bp MCK core promoter (proximal region). Following the core promoter, the construct included a 53 bp endogenous mouse MCK exon 1 (untranslated) for efficient transcription initiation, followed by an SV40 late 16S / 19S splice signal (97 bp) and a small 5'UTR (61 bp). The intron and 5'UTR were derived from plasmid pCMVβ(Clontech). The microdystrophin cassette has a common Kozak immediately before the start of ATG and a small 53 bp synthetic poly(A) signal at mRNA termination. The human microdystrophin cassette contains the (R4~R23 / Δ71~78) domain, which was previously described by Harper et al., Nat. Med. 8(3):253~61, 2002.

[0192] The pAAV.MCK.microdystrophin plasmid contained a human microdystrophin cDNA expression cassette adjacent to the AAV2 inverted terminal repeat (ITR) (see Figure 5). This sequence was capsidized onto the AAVrh.74 virion. Molecular clones of the AAVrh.74 serotype were cloned from the lymph nodes of rhesus monkeys and described by Rodino-Klapac et al., Journal of Tran. Med. 45 (2007).

[0193] References [ka] [ka] [ka]

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

change

Claims

1. A composition for treating muscular dystrophy in human subjects requiring treatment for muscular dystrophy, wherein the composition comprises recombinant adeno-associated virus (rAAV) of serotype rh. 74 comprising a polynucleotide containing the nucleotide sequence of SEQ ID NO: 9, the composition is formulated for intravenous administration, and the rAAV of serotype rh. 74 is present in a quantity of 5.0 × 10⁻¹⁴. １２ ~1.0 x 10 １５ A composition administered at a dose of vg / kg.

2. The composition according to claim 1, wherein the subject has a serum creatine kinase (CK) level > 1000 U / L prior to administration of the rAAV of serotype rh. 74 to the subject.

3. The composition according to claim 1 or 2, wherein the subject is below average in the Bayley-III exercise evaluation before administration of the rAAV of serotype rh. 74 to the subject.

4. The composition according to any one of claims 1 to 3, wherein the subject is below average in a 100-meter time-in-time test before administration of the rAAV of serotype rh. 74 to the subject.

5. The composition according to any one of claims 1 to 4, wherein the subject has an AAVrh. 74 or AAV8 antibody titer <1:400, which was determined by an ELISA immunoassay prior to administration of the rAAV of serotype rh. 74 to the subject.

6. The composition according to any one of claims 1 to 5, wherein the human subject is between 3 months and 7 years of age.

7. The composition according to any one of claims 1 to 6, wherein the dose of the rAAV of serotype rh. 74 is determined by using a supercoiled DNA standard.

8. The composition according to any one of claims 1 to 7, wherein the dose of the rAAV of serotype rh. 74 is about 10 mL / kg.

9. The composition according to any one of claims 1 to 8, wherein the composition is formulated for administration by injection or infusion.

10. The composition according to any one of claims 1 to 9, wherein the muscular dystrophy is Duchenne muscular dystrophy or Becker muscular dystrophy.

11. A composition for treating Duchenne muscular dystrophy in human subjects requiring treatment for Duchenne muscular dystrophy, wherein the composition comprises recombinant adeno-associated virus (rAAV) of serotype rh. 74, and the composition is administered by intravenous infusion over approximately 1 hour at a rate of 5.0 × 10⁻¹⁴. １２ ~1.0 x 10 １５ A composition formulated for administration at a dose of vg / kg, wherein the rAAV of serotype rh. 74 comprises a polynucleotide containing the nucleotide sequence of SEQ ID NO:

9.

12. The composition according to claim 11, wherein the subject has a Duchenne muscular dystrophy gene with an immature stop codon mutation or frameshift in exons 18-58.

13. The composition according to claim 11 or 12, wherein the subject has a serum creatine kinase (CK) level > 1000 U / L prior to administration of the rAAV of serotype rh. 74 to the subject.

14. The composition according to any one of claims 11 to 13, wherein the subject is below average in the Bayley-III exercise evaluation before administration of the rAAV of serotype rh. 74 to the subject.

15. The composition according to any one of claims 11 to 14, wherein the subject is below average in a 100-meter time-in-time test before administration of the rAAV of serotype rh. 74 to the subject.

16. The composition according to any one of claims 11 to 15, wherein the subject has an AAVrh. 74 or AAV8 antibody titer <1:400, which was determined by an ELISA immunoassay prior to administration of the rAAV of serotype rh. 74 to the subject.

17. The composition according to any one of claims 11 to 16, wherein the human subject is between 3 months and 7 years of age.

18. The composition according to any one of claims 11 to 17, wherein the dose of the rAAV of serotype rh. 74 is determined by using a supercoiled DNA standard.

19. The use of recombinant adeno-associated virus (rAAV) of serotype rh.74 containing a polynucleotide including the nucleotide sequence of SEQ ID NO: 9 for the preparation of a pharmaceutical for the treatment of muscular dystrophy in human subjects requiring treatment of muscular dystrophy, wherein the pharmaceutical is formulated for intravenous administration and is 5.0 × 10 １２ ~1.0 x 10 １５ Use comprising a dose of the aforementioned rAAV for serotype rh. 74 at vg / kg.

20. The use according to claim 19, wherein the subject has a serum creatine kinase (CK) level > 1000 U / L prior to administration of the rAAV of serotype rh. 74 to the subject.

21. The use according to claim 19 or 20, wherein the subject is below average on the Bayley-III exercise assessment before administration of the rAAV of serotype rh. 74 to the subject.

22. The use according to any one of claims 19 to 21, wherein the subject is below average in a 100-meter time-based test prior to administration of the rAAV of serotype rh. 74 to the subject.

23. The use according to any one of claims 19 to 22, wherein the subject has an AAVrh. 74 or AAV8 antibody titer <1:400, which was determined by an ELISA immunoassay prior to administration of the rAAV of serotype rh. 74 to the subject.

24. The use according to any one of claims 19 to 23, wherein the human subject is between 3 months and 7 years of age.

25. The use according to any one of claims 19 to 24, wherein the dose of the rAAV of serotype rh. 74 is determined using a supercoiled DNA standard.

26. The use according to any one of claims 19 to 25, wherein the dose of rAAV of serotype rh. 74 is formulated for administration at approximately 10 mL / kg.

27. The use according to any one of claims 19 to 26, wherein the pharmaceutical product is formulated for intravenous administration by infusion over approximately one hour.

28. The use according to any one of claims 19 to 27, wherein the muscular dystrophy is Becker muscular dystrophy.

29. The use of recombinant adeno-associated virus (rAAV) serotype rh.74 for the preparation of a pharmaceutical for the treatment of Duchenne muscular dystrophy in human subjects requiring treatment for Duchenne muscular dystrophy, wherein the pharmaceutical is formulated for administration by intravenous infusion over approximately one hour, and is 5.0 × 10⁻⁶. １２ ~1.0 x 10 １５ Use comprising a dose of vg / kg of the rAAV of serotype rh. 74, wherein the rAAV of serotype rh. 74 comprises a polynucleotide having the nucleotide sequence of SEQ ID NO:

9.

30. The use according to claim 29, wherein the subject has a Duchenne muscular dystrophy gene with an immature arrest codon mutation or frameshift in exons 18-58.

31. The use according to claim 29 or 30, wherein the subject has a serum creatine kinase (CK) level > 1000 U / L prior to administration of the rAAV of serotype rh. 74 to the subject.

32. The use according to any one of claims 29 to 31, wherein the subject is below average in the Bayley-III exercise evaluation before administration of the rAAV of serotype rh. 74 to the subject.

33. The use according to any one of claims 29 to 32, wherein the subject is below average in a 100-meter time-based test prior to administration of the rAAV of serotype rh. 74 to the subject.

34. The use according to any one of claims 29 to 33, wherein the subject has an AAVrh. 74 or AAV8 antibody titer <1:400, which was determined by an ELISA immunoassay prior to administration of the rAAV of serotype rh. 74 to the subject.

35. The use according to any one of claims 29 to 34, wherein the human subject is between 3 months and 7 years of age.

36. The use according to any one of claims 29 to 35, wherein the dose of the rAAV of serotype rh. 74 is determined using a supercoiled DNA standard.

37. After administration of the composition to a human subject requiring treatment for muscular dystrophy, the serum CK level in the subject was compared to the serum CK level before administration of the composition. a) At least 78% within 90, 180, or 270 days after the administration; b) at least 46, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, or 85% within 270 days after the administration; c) at least 72, 73, 74, or 95% within 180 days after the administration; d) at least 87, 88, 93, or 95% within 90 days after the administration; e) at least 70% within 270 days after the administration; f) 70-95% within 90, 180, or 270 days after the administration; and g) At least 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% within 90, 180, or 270 days after the administration. The composition according to any one of claims 1 to 18, which decreases at a percentage level selected from the group consisting of the following.

38. The composition according to any one of claims 1 to 18 or 37, wherein the level of microdystrophin gene expression in the target cells increases after administration of the rAAV of serotype rh. 74 compared to the level of microdystrophin gene expression before administration of the rAAV of serotype rh.

74.

39. The composition according to any one of claims 1 to 18 or 37 to 38, wherein the number of microdystrophin-positive fibers in the target muscle tissue increases after administration of the rAAV of serotype rh. 74 compared to the number of microdystrophin-positive fibers before administration of the rAAV of serotype rh.

74.

40. The composition according to any one of claims 1 to 18 or 37 to 39, wherein the level of α-sarcoglycan and / or β-sarcoglycan in the subject increases after administration of the rAAV of serotype rh. 74, compared to the level of α-sarcoglycan and / or β-sarcoglycan before administration of the rAAV of serotype rh.

74.

41. The composition according to any one of claims 1 to 18 or 37 to 40, wherein the progression of the disease in the subject is slowed after administration of the rAAV of serotype rh. 74, as measured by any one of the following: a six-minute walk test, time to stand, time to climb four stairs, time to climb and descend four stairs, Northstar Walk Assessment (NSAA), 10-meter timed test, 100-meter timed test, handheld strength measurement (HHD), timed-up-and-go, and / or gross motor subtest measurement (Bayley-III) score.

42. The serum CK level in the subject was compared to the serum CK level before administration of the rAAV of serotype rh. 74, and after administration of the rAAV of serotype rh. 74 to the subject, a) At least 78% within 90, 180, or 270 days after the administration; b) at least 46, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, or 85% within 270 days after the administration; c) at least 72, 73, 74, or 95% within 180 days after the administration; d) at least 87, 88, 93, or 95% within 90 days after the administration; e) at least 70% within 270 days after the administration; f) 70-95% within 90, 180, or 270 days after the administration; and g) At least 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, or 95% within 90, 180, or 270 days after the administration. The use according to any one of claims 19 to 36, wherein the reduction is at a percentage level selected from the group consisting of the following.

43. The use according to any one of claims 19 to 36 or 42, wherein the level of microdystrophin gene expression in the target cells increases after administration of the rAAV of serotype rh. 74 compared to the level of microdystrophin gene expression before administration of the rAAV of serotype rh.

74.

44. The use according to any one of claims 19 to 36 or 42 to 43, wherein the number of microdystrophin-positive fibers in the muscle tissue of the subject increases after administration of the rAAV of serotype rh. 74 compared to the number of microdystrophin-positive fibers before administration of the rAAV of serotype rh.

74.

45. The use according to any one of claims 19 to 36 or 42 to 44, wherein the levels of α-sarcoglycan and / or β-sarcoglycan in the subject increase after administration of the rAAV of serotype rh. 74 compared to the levels of α-sarcoglycan and / or β-sarcoglycan before administration of the rAAV of serotype rh.

74.

46. The use according to any one of claims 19-36 or 42-45, wherein the progression of the disease in the subject is slowed after administration of the rAAV of serotype rh. 74, as measured by any one of the following: a six-minute walk test, time to stand, time to climb four stairs, time to climb and descend four stairs, Northstar Walk Assessment (NSAA), 10-meter timed test, 100-meter timed test, handheld strength measurement (HHD), timed-up-and-go, and / or gross motor subtest measurement (Bayley-III) score.

Images